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ABSTRACT

The invention relates to the identification of fusion proteins
comprising polypeptide and protein variants of fibroblast
growth factor 21 (FGF21) with improved pharmaceutical
properties. Also disclosed are methods for treating FGF21
associated disorders, including metabolic conditions.
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FUSION PROTEINS FORTREATING
METABOLIC DISORDERS
FIELD OF THE INVENTION

0001. The present invention relates to new fusion proteins
comprising fibroblast growth factor 21 (FGF21) known to
improve metabolic profiles in subjects to whom they are
administered.
BACKGROUND OF THE INVENTION

0002. The fibroblast growth factor (FGF) family is char
acterized by 22 genetically distinct, homologous ligands,
which are grouped into seven subfamilies. FGF-21 is most
closely related to, and forms a subfamily with, FGF-19 and
FGF-23. This FGF subfamily regulates diverse physiological
processes uncommon to classical FGFs, namely energy and
bile acid homeostasis, glucose and lipid metabolism, and
phosphate as well as Vitamin D homeostasis. Moreover,
unlike other FGFs, this subfamily acts in an endocrine fash
ion. (Moore, D. D. (2007) Science 316, 1436-8) (Beenken et
al. (2009) Nature Reviews Drug Discovery 8, 235).
0003 FGF21 is a 209 amino acid polypeptide containing a
28 amino acid leader sequence (SEQ ID NO:5). Human
FGF21 has about 79% amino acid identity to mouse FGF21
and about 80% amino acid identity to rat FGF21. Fibroblast
growth factor 21
0004 (FGF21) has been described as a treatment for
ischemic vascular disease, wound healing, and diseases asso
ciated with loss of pulmonary, bronchia or alveolar cell func
tion. (Nishimura et al. (2000) Biochimica et Biophysica Acta,
1492:203-206: patent publication WO01/36640; and patent
publication WO01/18172) Although FGF-21 activates FGF
receptors and downstream signaling molecules, including
FRS2a and ERK, direct interaction of FGFRs and FGF-21 has

not been detected. Studies have identified B-klotho, which is
highly expressed in liver, adipocytes and pancreas, as a deter
minant of the cellular response to FGF-21 and a cofactor
which mediates FGF-21 signaling through FGFRs (Kurosu,
H. et al. (2007) J Biol Chem 282, 26687-95). FGF21 is a
potentagonist of the FGFR1 (IIIc), FGFR2(IIIc) and FGFR3
(IIIc) B-klotho signaling complexes.
0005 FGF-21 has been shown to induce insulin-indepen
dent glucose uptake. FGF-21 has also been shown to amelio
rate hyperglycemia in a range of diabetic rodent models. In
addition, transgenic mice over-expressing FGF-21 were
found to be resistant to diet-induced metabolic abnormalities,

and demonstrated decreased body weight and fat mass, and
enhancements in insulin sensitivity (Badman, M. K. et al.
(2007) Cell Metab 5, 426-37). Administration of FGF-21 to
diabetic non-human primates caused a decline in fasting
plasma glucose, triglycerides, insulin and glucagon levels,
and led to significant improvements in lipoprotein profiles
including a nearly 80% increase in HDL cholesterol (Khari
tonenkov, A. et al. (2007) Endocrinology 148, 774-81).
Recent studies investigating the molecular mechanisms of
FGF21 action have identified FGF21 as an important endo
crine hormone that helps to control adaptation to the fasting
state. (Badman et al. (2009) Endocrinology 150, 4931) (Ina
gaki et al. (2007) Cell Metabolism 5, 415) This provides a
previously missing link downstream of PPARC, by which the
liver communicates with the rest of the body in regulating the
biology of energy homeostasis. (Galman et al. (2008) Cell
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Metabolism 8,169) (Lundasen et al. (2007) Biochemical and
Biophysical Research Communications 360, 437).
0006 FGF21 regulates adipocyte homeostasis through
activation of an AMPK/SIRT1/PGC1C. pathway to inhibit
PPARY expression and increase mitochondrial function.
(Chau et al. (2010) PNAS 107, 12553) FGF21 also increases
glucose uptake by skeletal muscle as measured in cultured
human myotubes and isolated mouse tissue. FGF21 treatment
of rodent islet cells leads to improved function and survival
through activation of ERK1/2 and Akt pathways. (Wente et al.
(2006) Diabetes 55, 2470) FGF21 treatment also results in
altered gene expression for lipogenesis and fatty acid oxida
tion enzymes in rodent livers, likely through HNF4C. and
Foxa2 signaling.
0007. A difficulty associated with using FGF-21 directly
as a biotherapeutic is that its half-life is very short. (Khari
tonenkov, A. et al. (2005) Journal of Clinical Investigation
115:1627-1635) In mice, the half-life of human FGF21 is 0.5
to 1 hours, and in cynomolgus monkeys, the half-life is 2 to 3
hours. FGF21 may be utilized as a multi-use, sterile pharma
ceutical formulation. However, it has been determined that

preservatives, i.e., m-cresol, have an adverse affect on its
stability under these conditions.
0008. In developing an FGF21 protein for use as a thera
peutic in the treatment of type 1 and type 2 diabetes mellitus
and other metabolic conditions, an increase in half-life and

stability would be desirable. FGF21 proteins having
enhanced half-life and stability would allow for less frequent
dosing of patients being administered the protein. Clearly,
there is a need to develop a stable aqueous protein formula
tion for the therapeutic protein FGF21.
0009 Furthermore, significant challenge in the develop
ment of FGF21 as a protein pharmaceuticals, is to cope with
its physical and chemical instabilities. The compositional
variety and characteristics of proteins define specific behav
iors such as folding, conformational stability, and unfolding/
denaturation. Such characteristics should be addressed when

aiming to stabilize proteins in the course of developing phar
maceutical formulation conditions utilizing aqueous protein
solutions (Wang, W., Int. J. of Pharmaceutics, 18, (1999)). A
desired effect of stabilizing therapeutic proteins of interest,
e.g., the proteins of the present invention, is increasing resis
tance to proteolysis and enzymatic degradation, thereby
improving protein stability and reducing protein aggregation.
SUMMARY OF THE INVENTION

0010. The invention relates to the identification of new
fusion proteins which comprise fibroblast growth factor 21
(FGF21) and which have improved pharmaceutical proper
ties over the wild-type FGF21 and variants thereof under
pharmaceutical formulation conditions, e.g., are more stable,
possess the ability to improve metabolic parameters for Sub
jects to whom they are administered, are less Susceptible to
proteolysis and enzymatic degradation, and are less likely to
aggregate and form complexes. The fusion proteins of the
invention comprise truncations, mutations, and variants of
FGF21.

0011. Also disclosed are methods for treating FGF21-as
Sociated disorders, as well as other metabolic, endocrine, and

cardiovascular disorders, such as obesity, type 1 and type 2
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic
fatty liver disease (NAFLD), nonalcoholic steatohepatitis
(NASH), insulin resistance, hyperinsulinemia, glucose intol
erance, hyperglycemia, metabolic syndrome, acute myocar
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dial infarction, hypertension, cardiovascular disease, athero
Sclerosis, peripheral arterial disease, stroke, heart failure,
coronary heart disease, kidney disease, diabetic complica
tions, neuropathy, gastroparesis, disorders associated with
severe inactivating mutations in the insulin receptor, and
other metabolic disorders, and in reducing the mortality and
morbidity of critically ill patients.
0012. The fusion proteins of the present invention may be
used as a once weekly injectable either alone or in combina
tion with oral anti-diabetic agents which will improve the
glycemic control, body weight and lipid profile of type 1 and
type 2 diabetes mellitus patients. The proteins may also be
used for the treatment of obesity or other FGF21-associated
conditions.

0013 The fusion proteins of the invention overcome the
significant hurdles of physical instabilities associated with
protein therapeutics, including, for instance, with the admin
istration of the wild-type FGF21, by presenting proteins
which are more stable, less Susceptible to proteolysis and
enzymatic degradation, and less likely to aggregate and form
complexes, than wild-type FGF21 under pharmaceutical for
mulation conditions.

0014. In a first aspect, the invention provides Fibroblast
Growth Factor 21 (FGF21) fusion proteins comprising one or
more of the sequences listed in Table 1, and further described
herein. The FGF21 sequences listed in Table 1 may be vari
ants of the wild-type FGF21 sequence, e.g., the wild-type
FGF21 sequence with NCBI reference number NP 061986.
1, and found in such issued patents as, e.g., U.S. Pat. No.
6,716,626B1, assigned to Chiron Corporation.
0015 Said fusions may be, for example, between the vari
ant FGF21 sequences, e.g., the sequences of Table 1, and
other molecules (a non-FGF21 portion), e.g., an IgG constant
domain or fragment thereof (e.g., the Fc region), Human
Serum Albumin (HSA), or albumin-binding polypeptides. In
a preferred embodiment, the non-FGF21 portion of the mol
ecule is an Fc region.
0016 Other embodiments are drawn to polynucleotides
encoding the fusion proteins of the invention, a vector con
taining said polynucleotides and a host cell carrying said
Vector.

0017 Provided herein are methods used to generate the
fusion proteins of the invention, wherein such methods
involve modification of the wild-type FGF21 protein, via e.g.,
the site-specific incorporation of amino acids at positions of
interest within the wild-type FGF21 protein, as well as the
fusion between the FGF21 portion of the molecule to other
molecules, e.g., an IgG constant domain or fragment thereof
(e.g., the Fc region), Human Serum Albumin (HSA), or albu
min-binding polypeptides. Said modifications and fusions
enhance the biological properties of the fusion proteins of the
invention relative to the wild-type versions of the proteins as
well as, in some cases, serving as points of attachment for,
e.g., labels and protein half-life extension agents, and for
purposes of affixing said variants to the Surface of a Solid
support. Related embodiments of the invention are methods
to produce cells capable of producing said proteins of the
invention, and of producing vectors containing DNA encod
ing said variants and fusions.
0018. In various embodiments, the fusion proteins of the
invention disclosed herein can comprise one or more frag
ments of the FGF21 wild-type sequences, including frag
ments as Small as 8-12 amino acid residues in length, and
wherein the polypeptide is capable of lowering blood glucose
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in a mammal. In various embodiments, the fusion proteins of
the invention disclosed herein can comprise one or more
variant of the FGF21 wild-type sequences, e.g., with one or
more amino acid deletion, insertion, addition, or Substitution

relative to the wild-type sequences thereof.
0019. In some embodiments, the fusion proteins of the
invention disclosed herein can be covalently linked to one or
more polymers, such as polyethylene glycol (PEG) or poly
sialic acid, whether at the position of site-specific amino acid
modifications made relative to the wild-type FGF21, or at the
position of amino acids commonly shared with the wild-type
versions of those proteins. The PEG group is attached in such
away so as enhance, and/or not to interfere with, the biologi
cal function of the constituent portions of the fusion proteins
of the invention, e.g., the FGF21 protein variants. In other
embodiments, the polypeptides of the invention can be fused
to a heterologous amino acid sequence, optionally via a
linker, such as GS, GGGGSGGGGSGGGGS (SEQ ID
NO:6). The heterologous amino acid sequence can be an IgG
constant domain or fragment thereof (e.g., the Fc region),
Human Serum Albumin (HSA), or albumin-binding polypep
tides. Such fusion proteins disclosed herein can also form
multimers.

0020. In some embodiments, a heterologous amino acid
sequence (e.g., HSA, Fc, etc.) is fused to the amino-terminal
of the fusion proteins of the invention. In other embodiments,
the fusion heterologous amino acid sequence (e.g., HSA, Fc.
etc.) is fused to the carboxyl-terminal of the fusion proteins of
the invention.

0021. Yet another embodiment is drawn to methods of
treating a patient exhibiting one or more FGF21-associated
disorders, such as obesity, type 2 diabetes mellitus, type 1
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic
fatty liver disease (NAFLD), nonalcoholic steatohepatitis
(NASH), insulin resistance, hyperinsulinemia, glucose intol
erance, hyperglycemia, metabolic syndrome, acute myocar
dial infarction, hypertension, cardiovascular disease, athero
Sclerosis, peripheral arterial disease, stroke, heart failure,
coronary heart disease, kidney disease, diabetic complica
tions, neuropathy, gastroparesis, disorders associated with
inactivating mutations in the insulin receptor, and other meta
bolic disorders, comprising administering to said patient in
need of such treatment a therapeutically effective amount of
one or more proteins of the invention or a pharmaceutical
composition thereof.
0022. The invention also provides pharmaceutical compo
sitions comprising the fusion proteins of the invention dis
closed herein and a pharmaceutically acceptable formulation
agent. Such pharmaceutical compositions can be used in a
method for treating a metabolic disorder, and the method
comprises administering to a human patient in need thereof a
pharmaceutical composition of the invention. Non-limiting
examples of metabolic disorders that can be treated include
type 1 and type 2 diabetes mellitus and obesity.
0023 These and other aspects of the invention will be
elucidated in the following detailed description of the inven
tion.
BRIEF DESCRIPTION OF THE DRAWINGS

(0024 FIGS. 1A-1D show V188 has improved efficacy in
the ob/ob diabetic mouse model over V76. V188 shows supe
rior results when administered at 1 milligram per kilogram
(mpk), compared to the 5 milligram per kilogram at which
V76 was administered. FIG. 1A shows fed plasma glucose as
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a readout (circles represent vehicle (PBS phosphate buff
ered saline), squares represent V76 at 5 mpk, and triangles
representV188 at 1 mpk. FIG.1B shows fed plasma insulinas
a readout (from left to right: vehicle, V76 at 5 mpk, and V188
at 1 mpk). FIG. 1C shows body weight as a readout (from left
to right: vehicle, V76 at 5 mpk, and V188 at 1 mpk). FIG. 1D
shows liver lipid content as a readout (from left to right:
vehicle, V76 at 5 mpk, and V188 at 1 mpk).
0025 FIGS. 2A-2D show V101 has improved efficacy in
the ob/ob diabetic mouse model over V76. V101 shows supe
rior results when administered at 1 milligram per kilogram
(mpk), compared to the 5 milligram per kilogram at which
V76 was administered. FIG. 2A shows fed plasma glucose as
a readout (circles represent vehicle (PBS phosphate buff
ered saline), squares represent V76 at 5 mpk, and triangles
representV101 at 1 mpk. FIG.2B shows fed plasma insulinas
a readout (from left to right: vehicle, V76 at 5 mpk, and V101
at 1 mpk). FIG. 2C shows body weight as a readout (from left
to right: vehicle, V76 at 5 mpk, and V101 at 1 mpk). FIG. 2D
shows liver lipid content as a readout (from left to right:
vehicle, V76 at 5 mpk, and V101 at 1 mpk).
0026 FIGS. 3A-3D show V103 has improved efficacy in
the ob/ob diabetic mouse model over V76. V103 shows supe
rior results when administered at 1 milligram per kilogram
(mpk), compared to the 5 milligram per kilogram at which
V76 was administered. FIG. 3A shows fed plasma glucose as
a readout (circles represent vehicle (PBS phosphate buff
ered saline), squares represent V76 at 5 mpk, and triangles
representV103 at 1 mpk. FIG.3B shows fed plasma insulinas
a readout (from left to right: vehicle, V76 at 5 mpk, and V103
at 1 mpk). FIG. 3C shows body weight as a readout (from left
to right: vehicle, V76 at 5 mpk, and V103 at 1 mpk).
0027 FIG. 3D shows liver lipid content as a readout (from
left to right: vehicle, V76 at 5 mpk, and V103 at 1 mpk).
0028 FIGS. 4A-4D demonstrate the Superior pharmaco
kinetic and thermocynamic properties possessed by the
Met Asp

fusion proteins of the invention over FGF21 fusion proteins in
the art. FIG. 4A shows the plasma concentrations of fusion
proteins of the invention in PCT Publication WO10/129,600
described as Fc-L(15)-FGF21 (L98R, P171G) and Fc-L(15)FGF21 (L98R, P171G, A180E), following the IV injection of
said fusion in mice. FIG. 4B shows pharmacokinetic proper
ties of the fusion proteins of the invention (V101, V103 &
V188) after a single IV dose in the mouse as assayed by
anti-Fc-ELISA compared with pharmacokinetic data gener
ated in the mouse for V76 in a previous study using an anti
FGF21 antibody ELISA. FIG. 4C shows a spot check of the
fusion proteins of the invention in an anti-FGF21 Western
blot, consistent with anti-Fc-ELISA data at 120 hours and 15

days. The samples in the blot are as follows: A represents
V101, B represents V103, and C represents V188. Control is
V101 and serum. FIG. 4D demonstrates the significantly
increased thermodynamic stability of the fusion proteins of
the invention compared to V76. From top to bottom, the figure
represents V101, V103, and V188, all of which have
improved melting temperatures (T,) compared to V76
(T<50° C. (not shown)) and wild-type FGF21 (T46.5
C+0.3 (not shown)).
DETAILED DESCRIPTION OF THE INVENTION

0029. The fusion proteins of the present invention repre
sent modified versions of the full length, wild-type FGF21
polypeptide, as known in the art. FGF21 wild-type sequence
will serve as a reference sequence (SEQ ID NO:1), for
instance, when comparisons between the FGF21 wild-type
sequence and the protein variants are necessary. The FGF21
wild-type sequence has NCBI reference sequence number
NP 061986.1, and can be found in such issued patents as,
e.g., U.S. Pat. No. 6,716,626B1, assigned to Chiron Corpo
ration (SEQID NO:1).
Ser

Asp Glu

1.

Thir

Gly Phe

Glu His Ser

Gly Lieu. Trp

5

Wall Lieu Ala

Wall Ser
15

Gly Lieu Lleu Lieu. Gly

Ala

Glin Ala

His

Pro Ile Pro
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Asp Ser

Ser
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Pro Luell Lell Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr
4O
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Lieu. Tyr Thir Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu Ile Arg
SO

Glu

55

6O

Asp Gly Thir Wall Gly Gly Ala Ala Asp Glin Ser Pro
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Glu Ser Luell

70

Lieu. Glin Luell

Ala

Lieu Lys Pro Gly Wall Ile Glin

85

Thir Ser Arg Phe Lieu.

95

Cys Glin Arg Pro Asp Gly
105

Ser Luell His Phe Asp Pro Glu Ala
115
12 O

Glu Asp Gly
His Lieu. Pro

Ser Phe

Cell Lieu. Luell

Lel

150

Arg Phe

Pro Leu

Arg Gly

Gly Asn Lys Ser Pro His Arg Asp Pro

145

Pro Ala

Lel Tyr Gly
11 O

Asn Wall Tyr Glin Ser Glu Ala His
135
14 O

13 O

Lieu. Gly Val

90

155

Leul Pro Leu Pro Gly Leul Pro Pro
1.65
17O

160

Lel

Pro Glu
17s

US 2013/007.9500 A1

Mar. 28, 2013

- Continued
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp
18O

185

19 O

Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala
195

2OO

2O5

Ser
209

0030 The corresponding mRNA sequence coding for the
full-length FGF21 polypeptide (NCBI reference sequence
number NM 019113.2) is shown below (SEQ ID NO:2)
Ctgtcagctg aggat.ccagc cgaaagagga gccaggcact caggccacct gagt ct actic

61 acctggacaa citggaatctg goaccaattic taaac cactic agctitct cog agct cacacc
121 ccggagat.ca cct gaggacc cagc cattg atggacticgg acgaga.ccgg gttctgagcac
181 tdaggactgt gggtttctgt gctggctggit Cttctgctgg gagcctgcca gg cacacccC
241 atcc.ctgact c cagt cct ct cotgcaattic gggggccaag to cqgcagog gtacct citac
301 acagatgatg cccagcagac agaagcc cac ctggagat.ca gggaggatgg gacggtgggg
361 ggcgctgctg accagagcCC cqaaagt ct c ctgcagctga aagccttgaa gC cgggagtt
421 attcaaatct tdgagt cala gacat coagg tt CCtgtgcc agcggccaga tiggggg cctg
481 tatggat.cgc. tcc actittga CCCtgaggcc ticagottcc gggagctgct tcttgaggac
541 ggatacaatgtttaccagtic cqaagcc cac ggcct cocgc tigcacct gcc agggaacaag
601 tocccacacc gggaccctgc accc.cgagga ccagotcgct tcct gcc act accaggcctg
661 ccc.ccc.gcac toccggagcc acccggaatc ct gg.ccc.ccc agc.ccc.ccga tigtgggcticc
721 toggaccCt c taggatggit gggacct tcc cagggcc.gala gCCC cagct a cqct tcctga
781 agccagaggc tigtttact at gacat ct cot ctittattitat taggittattt at cittattta
841 ttitttittatt tttct tactt gagataataa agagttccag aggagaaaaa aaaaaaaaaa
90

aaaaaaaaaa aaaaaaaaaa

aaaaaaaaaa

aaaaaaaaaa.

0031. The mature FGF21 sequence lacks a leader
sequence and may also include other modifications of a
polypeptide Such as proteolytic processing of the amino ter
minus (with or without a leader sequence) and/or the carboxyl
terminus, cleavage of a smaller polypeptide from a larger
precursor, N-linked and/or O-linked glycosylation, and other

post-translational modifications understood by those with
skill in the art. A representative example of a mature FGF21
sequence has the following sequence (SEQID NO:3, which
represents amino acid positions 29-209 of full length FGF21
protein sequence (NCBI reference sequence number
NP 061986.1)):

His Pro Ile Pro Asp Ser Ser Pro Lieu. Lieu. Glin Phe

Gly Gly

Glin

Wall

15

Arg Glin Arg Tyr Lieu. Tyr Thir Asp Asp Ala Glin Glin. Thir Glu Ala His
25
Lell Glu Ile
35

Arg Glu Asp Gly

Thir Wall

Lieu. Gly

Wall

65

Ala

Gly Gly

Ala Ala

4O

Pro Glu Ser Lieu. Luell Glin Lell
SO
55

Ile

3O

Ala Luell Lys Pro Gly Wall Ile Glin
60

Thir

Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly

70

8O

Leu Tyr Gly Ser Lieu. His
85

Asp Glin Ser

45

Phe

Asp

Pro Glu Ala
90

Ser Phe
95

Arg
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- Continued
Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His
1OO

105

11 O

Gly Lieu Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro
115

12 O

125

Ala Pro Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu.
13 O

135

Pro Pro

14 O

Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Wall
145

150

155

160

Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser
1.65

17O

17s

Pro Ser Tyr Ala Ser
18O

0032. The corresponding cDNA sequence coding for the
mature FGF21 polypeptide (SEQ ID NO:3) is shown below
(SEQ ID NO:4):
Caccc catcc ctgactic cag to Ctctic ctg caatt.cgggg gccaagt ccg gCagcggtac

61 Ctctacacag atgatgcc.ca gcagacagaa gC ccacctgg agat Caggga ggatgggacg
121 gtggggggcg Ctgctgacca gagcc.ccgala agtict Cotgc agctgaaagc Cttgaa.gc.cg
181 ggagittatt C aaatcttggg agt caagaca to Caggttcc titgc.ca.gcg gccagatggg
240 gocct gtatg gatcgct coa ctittgaccct gaggcctgca gct tccggga gotgctitctt

301 gaggacggat acaatgttta CcagtCc gala gCC CacggCC to CC gCtgca CCtgcCaggg
360 aacaagt ccc cacac cqgga ccctgcaccc cdaggaccag ct cqct tcct gccactacca
421 ggcctgccCC cc.gcact coc ggagccaccc ggaatcc tig cc ccc.ca.gcc ccc.cgatgtg
481 ggctic ct cqg accct ctgag catggtggga cct tcc.cagg gcc.gaag.ccc cagctacgct
541 toctda

0033. The fusion proteins of the invention may comprise
protein variants or mutants of the wild-type proteins listed
herein, e.g., FGF21 variants. As used herein, the terms “pro
tein variant,” “human variant,” “polypeptide or protein vari
ant.” “variant.” “mutant, as well as any like terms or specific
versions thereof (e.g., “FGF21 protein variant,” “variant.”
“FGF21 mutant, etc.) define protein or polypeptide
sequences that comprise modifications, truncations, other
variants of naturally occurring (i.e., wild-type) protein or
polypeptide counterparts or corresponding native sequences.

described relative to the wild-type (i.e., naturally occurring)
FGF21 protein as described herein.
0034 Representative fusion protein sequences of the
invention are listed in Table 1. The descriptions of said
fusions include the FGF21 variant and, where applicable, a
linker. The changes or substitutions employed by the FGF21
variant are numbered and described relative to wild-type
FGF21. By way of example, “Variant 101 (V101)” (SEQ ID
NO:10) is an Fc-FGF21 fusion with a two amino acid linker
and the following substitutions made relative to wild type
FGF21: Q55C, A109T, G148C, K150R, P158S, P174L,

“Variant FGF21 or “FGF21 mutant, for instance, is

S195A, P199G, G202A.
TABLE 1.

FGF21 Variant Fc fusion proteins
SEQ
ID

NO: Sequence
7 DKTHTCPPCP
LMSRTPEVT
GWEWHNAKTK

Namek

APEAAGGPSV FLFPPKPKDT Full Length N-term Fo-Fusion
CVVVDVSHED PEVKFNWYWD with 2 AA Linker (GS) and
PREEOYNSTY RVVSVLTVLH WT FGF21

ODWLNGKEYK CKWSNKALPA PIEKTISKAK
GOPREPOVYT LPPSREEMTK NOWSLTCLVK
GFYPSDIAWE WESNGOPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWOOG NWFSCSVMHE
ALHNHYTOKS
WRORYLYTDD AOOTEAHLEI REDGTWGGAA
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TABLE 1 - continued

FGF21 Variant Fc fusion proteins
SEQ
ID

NO: Sequence

Namek

SPHRDPASRG PARFLPLPGL PPALPEPPGI

LAPOPPDWGS SDPLAMWGGS QARSPSYAS
13 DKTHTCPPCP APEAAGGPSV FLFPPKPKDT Variant H2O4 = V101 with 15 AA
LMISRTPEVT CVVVDVSHED PEVKFNWYWD Linker (GGGGS x 3) between Fc

GWEVHNAKTK PREEOYNSTY RVVSVLTVLH and FGF21 = (Q55C, A109T
ODWLNGKEYK CKVSNKALPA PIEKTISKAK G148C

K15 OR

P158S, S195A,

GOPREPOVYT LPPSREEMTK NOVSLTCLVK P199G G2O2A)
GFYPSDIAVE WESNGOPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWOOG NWFSCSVMHE
ALHNHYTOKS LSLSPGKGGG GSGGGGSGGG

GSDSSPLLQF GGQVRQRYLY TDDACQTEAH
LEIREDGTWG GAADQSPESL LOLKALKPGV
IOILGVKTSR FLCORPDGTL YGSLHFDPEA
CSFRELLLED GYNWYOSEAH GLPLHLPCNR
SPHRDPASRG PARFLPLPGL PPALPEPPGI

LAPOPPDWGS SDPLAMWGGS QARSPSYAS
- Note

that the FGF21 wild-type sequence in this table refers to NCBI reference sequence
number NP O61986. 1 (SEQ ID NO: 1) unless otherwise specified.

All mutations in the FGF21 moiety and corresponding amino
acid numbering of said mutations refers back to (SEQ ID
NO: 1) not to the full-length sequences in this table which may
also include Fc and linker regions.
0035. The variants or mutants used in the fusion proteins
of the invention, e.g., variants of wild-type FGF21, feature at
least one Substituted, added, and/or removed amino acid rela

tive to the wild-type protein. Additionally, the variants may
include N- and/or C-terminal truncations relative to the wild

type proteins. Generally speaking, a variant possesses some
modified property, structural or functional, of the wild-type
protein. For example, the variant may have enhanced or
improved physical stability in concentrated solutions (e.g.,
less hydrophobic mediated aggregation), enhanced or
improved plasma stability when incubated with blood plasma
or enhanced or improved bioactivity while maintaining a
favorable bioactivity profile.
0036. Acceptable amino acid substitutions and modifica
tions which constitute differences between the portions of the
fusion proteins of the invention and their wild-type compara
torproteins include, but are not limited to, one or more amino
acid Substitutions, including Substitutions with non-naturally
occurring amino acid analogs, and truncations. Thus, the
fusion proteins of the invention (e.g., the fusion proteins of
the invention) include, but are not limited to, site-directed
mutants, truncated polypeptides, proteolysis-resistant
mutants, aggregation-reducing mutants, combination
mutants, and fusion proteins, as described herein.
0037. One skilled in the art of expression of proteins will
recognize that methionine or methionine-arginine sequence
can be introduced at the N-terminus of any of the fusion
proteins of the invention, for expression in E. coli, and are
contemplated within the context of this invention.
0038. The fusion proteins of the invention may possess
increased compatibility with pharmaceutical preservatives
(e.g., m-cresol, phenol, benzyl alcohol), thus enabling the
preparation of a preserved pharmaceutical formulation that
maintains the physiochemical properties and biological activ
ity of the protein during storage. Accordingly, variants with
enhanced pharmaceutical stability relative to wild-type, have

improved physical stability in concentrated solutions under
both physiological and preserved pharmaceutical formula
tion conditions, while maintaining biological potency. By
way of non-limiting example, the fusion proteins of the inven
tion may be more resistant to proteolysis and enzymatic deg
radation; may have improved Stability; and may be less likely
to aggregate, than their wild-type counterparts or correspond
ing native sequence. As used herein, these terms are not
mutually exclusive or limiting, it being entirely possible that
a given variant has one or more modified properties of the
wild-type protein.
0039. The invention also encompasses nucleic acid mol
ecules encoding the fusion proteins of the invention, compris
ing, for example, an FGF21 amino acid sequence that is at
least about 95% identical to the amino acid sequence of SEQ
ID NO:3, but wherein specific residues conferring a desirable
property to the FGF21 protein variant, e.g., improved potency
to FGF21-receptors, proteolysis-resistance, increased half
life or aggregation-reducing properties and combinations
thereof have not been further modified. In other words, with

the exception of residues in the FGF21 mutant sequence that
have been modified in order to confer proteolysis-resistance,
aggregation-reducing, or other properties, about 5% (alter
nately 4%, alternately 3%, alternately 2%, alternately 1%) of
all other amino acid residues in the FGF21 mutant sequence
can be modified. Such FGF21 mutants possess at least one
activity of the wild-type FGF21 polypeptide.
0040. The invention also encompasses a nucleic acid mol
ecule comprising a nucleotide sequence that is at least about
85%, identical, and more preferably, at least about 90 to 95%
identical to the nucleotide sequence of SEQID NO:2 or SEQ
ID NO:4, but wherein the nucleotides encoding amino acid
residues conferring the encoded protein's proteolysis-resis
tance, aggregation-reducing or other properties have not been
further modified. In other words, with the exception of nucle
otides that encode residues in the FGF21 mutant sequences
that have been modified in order to confer proteolysis-resis
tance, aggregation-reducing, or other properties, about 15%,
and more preferably about 10 to 5% of all other nucleotides in
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the mutant sequence can be modified. Such nucleic acid mol
ecules encode proteins possessing at least one activity of their
wild-type counterparts.
0041) Provided herein are methods used to generate the
fusion proteins of the invention, wherein such methods
involve site-specific modification and non-site-specific modi
fication of the wild-type versions of the proteins (e.g., the
FGF21 wild-type protein as described herein), e.g., trunca
tions of the wild-type proteins, and the site-specific incorpo
ration of amino acids at positions of interest within the wild
type proteins. Said modifications enhance the biological
properties of the fusion proteins of the invention relative to
the wild-type proteins, as well as, in some cases, serving as
points of attachment for, e.g., labels and protein half-life
extension agents, and for purposes of affixing said variants to
the surface of a solid support. Related embodiments of the
invention are methods of producing cells capable of produc
ing said Fusion Proteins of the invention, and of producing
vectors containing DNA encoding said variants.
0042. In certain embodiments, such modifications, e.g.,
site-specific modifications, are used to attach conjugates, e.g.,
PEG groups to proteins, polypeptides, and/or peptides of the
invention, for purposes of, e.g., extending half-life or other
wise improving the biological properties of said proteins,
polypeptides, and/or peptides. Said techniques are described

a branching point to allow more than one type of molecule to
be attached at a single site of a protein, polypeptide or peptide.
0047. In other embodiments, the modifications listed
herein can be done in a non-site-specific manner and result in
protein-protein conjugates, protein-polypeptide conjugates,
protein-peptide conjugates, polypeptide-polypeptide conju
gates, polypeptide-peptide conjugates or peptide-peptide
conjugates of the invention.

further herein.

constituent amino acid residues deleted, added, modified, or

0043. In other embodiments, such modifications, e.g.,
site-specific modifications, are used to attach other polymers,
small molecules and recombinant protein sequences that
extend half-life of the protein of the invention. One such
embodiment includes the attachment offatty acids or specific
albuminbinding compounds to proteins, polypeptides, and/or
peptides. In other embodiments, the modifications are made
at a particular amino acid type and may be attached at one or
more sites on the protein.
0044. In other embodiments, such modifications, e.g.,
site-specific modifications, are used as means of attachment
for the production of wild-type and/or variant multimers, e.g.,
dimers (homodimers or heterodimers) or trimers or tetramers.
These multimeric protein molecules may additionally have
groups such as PEG, Sugars, and/or PEG-cholesterol conju
gates attached or be fused either amino-terminally or car
boxy-terminally to other proteins such as Fc. Human Serum
Albumin (HSA), etc.
0045. In other embodiments, such site-specific modifica
tions are used to produce proteins, polypeptides and/or pep
tides wherein the position of the site-specifically incorporated
pyrrolysine or pyrrolysine analogue or non-naturally occur
ring amino acids (para-acetyl-Phe, para-azido-Phe) allows
for controlled orientation and attachment of Such proteins,
polypeptides and/or peptides onto a Surface of a solid Support
or to have groups such as PEG, sugars and/or PEG-choles
terol conjugates attached.
0046. In other embodiments, such site-specific modifica
tions are used to site-specifically cross-link proteins,
polypeptides and/or peptides thereby forming hetero-oligo
mers including, but not limited to, heterodimers and heterot
rimers. In other embodiments, such site-specific modifica
tions are used to site-specifically cross-link proteins,
polypeptides and/or peptides thereby forming protein-protein
conjugates, protein-polypeptide conjugates, protein-peptide
conjugates, polypeptide-polypeptide conjugates, polypep
tide-peptide conjugates or peptide-peptide conjugates. In
other embodiments, a site specific modification may include

DEFINITIONS

0048 Various definitions are used throughout this docu
ment. Most words have the meaning that would be attributed
to those words by one skilled in the art. Words specifically
defined either below or elsewhere in this document have the

meaning provided in the context of the present invention as a
whole and as are typically understood by those skilled in the
art.

0049. As used herein, the term “FGF21 refers to a mem
ber of the fibroblast growth factor (FGF) protein family. An
amino acid sequence of FGF21 (GenBank Accession No.
NP 061986.1) is set forth as SEQID NO:1, the correspond
ing polynucleotide sequence of which is set forth as SEQID
NO:2 (NCBI reference sequence number NM 019113.2).
“FGF21 variant,” “FGF21 mutant and similar terms

describe modified version of the FGF21 protein, e.g., with
substituted.

0050. As used herein, the term “FGF21 receptor” refers to
a receptor for FGF21 (Kharitonenkov, A. etal. (2008) Journal
of Cellular Physiology 215:1-7: Kurosu, Het al. (2007) JBC
282:26687-26695; Ogawa, Yet al. (2007) PNAS 104:7432
7437).
0051. The term “FGF21 polypeptide” refers to a naturally
occurring polypeptide expressed in humans. For purposes of
this disclosure, the term “FGF21 polypeptide' can be used
interchangeably to refer to any full-length FGF21 polypep
tide, e.g., SEQ ID NO:1, which consists of 209 amino acid
residues and which is encoded by the nucleotide sequence of
SEQ ID NO:2; any mature form of the polypeptide, which
consists of 181 amino acid residues, and in which the 28
amino acid residues at the amino-terminal end of the full

length FGF21 polypeptide (i.e., which constitute the signal
peptide) have been removed.
0052 “Variant 76,” as used herein, is an FGF21 protein
variant, featuring a 40 kDa branched PEG linked through
Cys 154, and eight point mutations relative to the 177 amino
acid wild-type protein. Synthesis of the variant is described in
greater detail herein, and the protein sequence is represented
in Table 1 and SEQID NO:9.
0053. The term “isolated nucleic acid molecule' refers to
a nucleic acid molecule of the present invention that (1) has
been separated from at least about 50 percent of proteins,
lipids, carbohydrates, or other materials with which it is natu
rally found when total nucleic acid is isolated from the source
cells, (2) is not linked to all or a portion of a polynucleotide to
which the "isolated nucleic acid molecule' is linked in nature,

(3) is operably linked to a polynucleotide which it is not
linked to in nature, or (4) does not occur in nature as part of a
larger polynucleotide sequence. Preferably, the isolated
nucleic acid molecule of the present invention is substantially
free from any other contaminating nucleic acid molecules or
other contaminants that are found in its natural environment

that would interfere with its use in polypeptide production or
its therapeutic, diagnostic, prophylactic or research use.
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0054) The term “vector” is used to refer to any molecule
(e.g., nucleic acid, plasmid, or virus) used to transfer coding
information to a host cell.

0055. The term “expression vector” refers to a vector that
is Suitable for transformation of a host cell and contains

nucleic acid sequences that direct and/or control the expres
sion of inserted heterologous nucleic acid sequences. Expres
sion includes, but is not limited to, processes such as tran
Scription, translation, and RNA splicing, if introns are
present.

0056. The term “operably linked' is used herein to refer to
an arrangement of flanking sequences wherein the flanking
sequences so described are configured or assembled so as to
perform their usual function. Elements of fusions proteins
may be operably linked to one another so as to allow the
fusion protein to function as if it were a naturally occurring,
endogenous protein, and/or to combine disparate elements of
said fusion proteins in a synergistic fashion.
0057. On a nucleotide level, a flanking sequence operably
linked to a coding sequence may be capable of effecting the
replication, transcription and/or translation of the coding
sequence. For example, a coding sequence is operably linked
to a promoter when the promoter is capable of directing
transcription of that coding sequence. A flanking sequence
need not be contiguous with the coding sequence, so long as
it functions correctly. Thus, for example, intervening untrans
lated yet transcribed sequences can be present between a
promoter sequence and the coding sequence and the promoter
sequence can still be considered "operably linked to the
coding sequence.
0058. The term “host cell is used to refer to a cell which
has been transformed, or is capable of being transformed with
a nucleic acid sequence and then of expressing a selected gene
of interest. The term includes the progeny of the parent cell,
whether or not the progeny is identical in morphology or in
genetic make-up to the original parent, so long as the selected
gene is present.
0059. The term “amino acid,” as used herein, refers to
naturally occurring amino acids, unnatural amino acids,
amino acid analogues and amino acid mimetics that function
in a manner similar to the naturally occurring amino acids, all
in their D and L stereoisomers if their structure allows such

stereoisomeric forms. Amino acids are referred to herein by
either their name, their commonly known three letter symbols
or by the one-letter symbols recommended by the IUPAC
IUB Biochemical Nomenclature Commission.

0060. The term “naturally occurring” when used in con
nection with biological materials such as nucleic acid mol
ecules, polypeptides, host cells, and the like, refers to mate
rials which are found in nature and are not manipulated by
man. Similarly, “non-naturally occurring as used herein
refers to a material that is not found in nature or that has been

structurally modified or synthesized by man. When used in
connection with nucleotides, the term “naturally occurring
refers to the bases adenine (A), cytosine (C), guanine (G),
thymine (T), and uracil (U). When used in connection with
amino acids, the term “naturally occurring refers to the 20
conventional amino acids (i.e., alanine (A), cysteine (C),
aspartic acid (D), glutamic acid (E), phenylalanine (F), gly
cine (G), histidine (H), isoleucine (I), lysine (K), leucine (L),
methionine (M), asparagine (N), proline (P), glutamine (Q).
arginine (R), serine (S), threonine (T), Valine (V), tryptophan
(W), and tyrosine (Y)), as well as selenocysteine, pyrrolysine
(Pyl, or O), and pyrroline-carboxy-lysine (Pcl, or Z).
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0061 Pyrrolysine (Pyl) is an amino acid naturally found
within methylamine methyltransferases of methanogenic
archaea of the family Methanosarcina. Pyrrolysine is alysine
analogue co-translationally incorporated at in-frame UAG
codons in the respective mRNA, and it is considered the 22nd
natural amino acid.

0062. As described at least in PCT patent publication
WO2010/48582 (applicant IRM, LLC), attempts to biosyn
thesize pyrrolysine (Pyl) in E. coli resulted in the formation of
a "demethylated pyrrolysine.” referred to herein as pyrroline
carboxy-lysine, or Pcl. “Pel,” as used herein, refers to either
Pcl-A or Pcl-B.

0063. The terms “non-natural amino acid' and “unnatural
amino acid, as used herein, are interchangeably intended to
representamino acid structures that cannot be generated bio
synthetically in any organism using unmodified or modified
genes from any organism, whether the same or different. The
terms refer to an amino acid residue that is not present in the
naturally occurring (wild-type) FGF21 protein sequence or
the sequences of the present invention. These include, but are
not limited to, modified amino acids and/or amino acid ana

logues that are not one of the 20 naturally occurring amino
acids, selenocysteine, pyrrolysine (Pyl), or pyrroline-car
boxy-lysine (Pcl, e.g., as described in PCT patent publication
WO2010/48582). Such non-natural amino acid residues can
be introduced by Substitution of naturally occurring amino
acids, and/or by insertion of non-natural amino acids into the
naturally occurring (wild-type) FGF21 protein sequence or
the sequences of the invention. The non-natural amino acid
residue also can be incorporated Such that a desired function
ality is imparted to the FGF21 molecule, for example, the
ability to link a functional moiety (e.g., PEG). When used in
connection with amino acids, the symbol “U” shall mean
“non-natural amino acid and "unnatural amino acid as used
herein.

0064. In addition, it is understood that such “unnatural
amino acids’ require a modified tRNA and a modified tRNA
synthetase (RS) for incorporation into a protein. These
“selected orthogonal tRNA/RS pairs are generated by a
selection process as developed by Schultz et al. or by random
or targeted mutation. As way of example, pyrroline-carboxy
lysine is a “natural amino acid as it is generated biosyntheti
cally by genes transferred from one organism into the host
cells and as it is incorporated into proteins by using natural
tRNA and tRNA synthetase genes, while p-aminophenylala
nine (See, Generation of a bacterium with a 21 amino acid
genetic code, Mehl RA. Anderson J C, Santoro SV V. Wang
L., Martin AB, King DS, Horn DM, Schultz PG. JAm Chem.
Soc. 2003 Jan. 29; 125(4):935-9) is an “unnatural amino
acid because, although generated biosynthetically, it is
incorporated into proteins by a “selected orthogonal tRNA/
tRNA synthetase pair.
0065 Modified encoded amino acids include, but are not
limited to, hydroxyproline, Y-carboxyglutamate, O-phospho
serine, aZetidinecarboxylic acid, 2-aminoadipic acid, 3-ami
noadipic acid, beta-alanine, aminopropionic acid, 2-ami
nobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid,
2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-ami
noisobutyric acid, 2-aminopimelic acid, tertiary-butylgly
cine, 2,4-diaminoisobutyric acid, desmosine, 2,2'-diami
nopimelic acid, 2,3-diaminoproprionic acid, N-ethylglycine,
N-methylglycine, N-ethylasparagine, homoproline,
hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hy
droxyproline, isodesmosine, allo-isoleucine, N-methylala
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nine, N-methylglycine, N-methylisoleucine, N-methylpen
tylglycine, N-methylvaline, naphthalanine, norvaline,
norleucine, ornithine, pentylglycine, pipecolic acid and thio
proline. The term “amino acid also includes naturally occur
ring amino acids that are metabolites in certain organisms but
are not encoded by the genetic code for incorporation into
proteins. Such amino acids include, but are not limited to,
ornithine, D-ornithine, and D-arginine.
0066. The term “amino acid analogue.” as used herein,
refers to compounds that have the same basic chemical struc
ture as a naturally occurring amino acid, by way of example
only, an O-carbon that is bound to a hydrogen, a carboxyl
group, an amino group, and an R group. Amino acid ana
logues include the natural and unnatural amino acids which
are chemically blocked, reversibly or irreversibly, or their
C-terminal carboxy group, their N-terminal amino group and/
or their side-chain functional groups are chemically modi
fied. Such analogues include, but are not limited to, methion
ine sulfoxide, methionine sulfone, S-(carboxymethyl)cysteine,
S-(carboxymethyl)-cysteine
Sulfoxide,
S-(carboxymethyl)-cysteine Sulfone, aspartic acid-(beta-me
thyl ester), N-ethylglycine, alanine carboxamide,
homoserine, norleucine, and methionine methyl sulfonium.
0067. The term “amino acid mimetics,” as used herein,
refers to chemical compounds that have a structure that is
different from the general chemical structure of an amino
acid, but functions in a manner similar to a naturally occurring
amino acid.

0068. The term “biologically active variant” refers to any
polypeptide variant used in the fusion proteins of the inven
tion, e.g., as a constituent protein of the fusions, that pos
sesses an activity of its wild-type (e.g., naturally-occurring)
protein or polypeptide counterpart, Such as the ability to
modulate blood glucose, HbAlc, insulin, triglyceride, or cho
lesterol levels; increase pancreatic function; reduce lipid lev
els in liver, reduce body weight; and to improve glucose
tolerance, energy expenditure, or insulin sensitivity, regard
less of the type or number of modifications that have been
introduced into the polypeptide variant. Polypeptide variants
possessing a somewhat decreased level of activity relative to
their wild-type versions can nonetheless be considered to be
biologically active polypeptide variants. A non-limiting rep
resentative example of a biologically active polypeptide vari
ant of the invention is an FGF21 variant, which is modified

after, and possesses similar or enhanced biological properties
relative to, wild-type FGF21.
0069. The terms “effective amount” and “therapeutically
effective amount each refer to the amount of a fusion protein
of the invention used to support an observable level of one or
more biological activities of the wild-type polypeptide or
protein counterparts, such as the ability to lower blood glu
cose, insulin, triglyceride or cholesterol levels; reduce liver
triglyceride or lipid levels; reduce body weight; or improve
glucose tolerance, energy expenditure, or insulin sensitivity.
For example, a “therapeutically-effective amount’ adminis
tered to a patient exhibiting, Suffering, or prone to Suffer from
FGF21-associated disorders (such as type 1 or type 2 diabetes
mellitus, obesity, or metabolic syndrome), is such an amount
which induces, ameliorates or otherwise causes an improve
ment in the pathological symptoms, disease progression,
physiological conditions associated with or resistance to Suc
cumbing to the afore mentioned disorders. For the purposes
of the present invention a “subject' or “patient' is preferably
a human, but can also be an animal, more specifically, a
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companion animal (e.g., dogs, cats, and the like), farm ani
mals (e.g., cows, sheep, pigs, horses, and the like) and labo
ratory animals (e.g., rats, mice, guinea pigs, and the like).
0070 The term “pharmaceutically acceptable carrier' or
“physiologically acceptable carrier as used herein refers to
one or more formulation materials suitable for accomplishing
or enhancing the delivery of a fusion protein of the invention.
0071. The term “antigen” refers to a molecule or a portion
of a molecule that is capable of being bound by an antibody,
and additionally that is capable of being used in an animal to
produce antibodies that are capable of binding to an epitope of
that antigen. An antigen may have one or more epitopes.
0072 The term “native Fc refers to molecule or sequence
comprising the sequence of a non-antigen-binding fragment
resulting from digestion of whole antibody or produced by
other means, whether in monomeric or multimeric form, and

can contain the hinge region. The original immunoglobulin
Source of the native Fc is preferably of human origin and can
be any of the immunoglobulins, although IgG1 and IgG2 are
preferred. Native Fc molecules are made up of monomeric
polypeptides that can be linked into dimeric or multimeric
forms by covalent (i.e., disulfide bonds) and non-covalent
association. The number of intermolecular disulfide bonds

between monomeric Subunits of native Fc molecules ranges
from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or
Subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2). One
example of a native Fc is a disulfide-bonded dimer resulting
from papain digestion of an IgG (see Ellison et al., 1982,
Nucleic Acids Res. 10:4071-9). The term “native Fc” as used
herein is generic to the monomeric, dimeric, and multimeric
forms.

0073. The term “Fc variant refers to a molecule or
sequence that is modified from a native Fc but still comprises
a binding site for the Salvage receptor, FcRn (neonatal Fc
receptor). International Publication Nos. WO97/34631 and
WO 96/32478 describe exemplary Fc variants, as well as
interaction with the Salvage receptor, and are hereby incor
porated by reference. Thus, the term “Fc variant can com
prise a molecule or sequence that is humanized from a non
human native Fc. Furthermore, a native Fc comprises regions
that can be removed because they provide structural features
or biological activity that are not required for the fusion
molecules of the fusion proteins of the invention. Thus, the
term "Fc variant comprises a molecule or sequence that
lacks one or more native Fc sites or residues, or in which one
or more Fc sites or residues has be modified, that affect or are

involved in: (1) disulfide bond formation, (2) incompatibility
with a selected host cell, (3) N-terminal heterogeneity upon
expression in a selected host cell, (4) glycosylation, (5) inter
action with complement, (6) binding to an Fc receptor other
than a salvage receptor, or (7) antibody-dependent cellular
cytotoxicity (ADCC). Fc variants are described in further
detail hereinafter.

0074 The term “Fc domain encompasses native Fc and
Fc variants and sequences as defined above. As with Fc vari
ants and native Fc molecules, the term "Fc domain includes
molecules in monomeric or multimeric form, whether

digested from whole antibody or produced by other means. In
Some embodiments of the present invention, an Fc domain
can be fused to FGF21 or a FGF21 mutant (including a
truncated form of FGF21 or a FGF21 mutant) via, for
example, a covalent bond between the Fc domain and the
FGF21 sequence. Such fusion proteins can form multimers
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via the association of the Fc domains and both these fusion

proteins and their multimers are an aspect of the present
invention.

0075. The term “modified Fc fragment”, as used herein,
shall mean an Fc fragment of an antibody comprising a modi
fied sequence. The Fc fragment is a portion of an antibody
comprising the CH2, CH3 and part of the hinge region. The
modified Fc fragment can be derived from, for example,
IgG1, IgG2, IgG3, or IgG4. FcLALA is a modified Fc frag
ment with a LALA mutation (L234A, L235A), which triggers
ADCC with lowered efficiency, and binds and activates
human complement weakly. Hessell et al. 2007 Nature 449:
101-104. Additional modifications to the Fc fragment are
described in, for example, U.S. Pat. No. 7,217,798.
0076. The term "heterologous' means that these domains
are not naturally found associated with constant regions of an
antibody. In particular, Such heterologous binding domains
do not have the typical structure of an antibody variable
domain consisting of 4 framework regions, FR1, FR2, FR3
and FR4 and the 3 complementarity determining regions
(CDRs) in-between. Each arm of the fusobody therefore com
prises a first single chain polypeptides comprising a first
binding domain covalently linked at the N-terminal part of a
constant C1 heavy chain region of an antibody, and a second
single chain polypeptide comprising a second binding
domain covalently linked at the N-terminal part of a constant
C light chain of an antibody. The covalent linkage may be
direct, for example via peptidic bound or indirect, via a linker,
for example a peptidic linker. The two heterodimers of the
fusobody are covalently linked, for example, by at least one
disulfide bridge at their hinge region, like an antibody struc
ture. Examples of molecules with a fusobody structure have
been described in the art, in particular, fuSobodies comprising
ligand binding region of heterodimeric receptor (see for
example international patent publications WOO1/46261 and
WO11/076,781).
0077. The term “polyethylene glycol” or “PEG” refers to
a polyalkylene glycol compound or a derivative thereof, with
or without coupling agents or derivatization with coupling or
activating moieties.
0078. The term “FGF21-associated disorders, and terms
similarly used herein, includes obesity, type 1 and type 2
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic
fatty liver disease (NAFLD), nonalcoholic steatohepatitis
(NASH), insulin resistance, hyperinsulinemia, glucose intol
erance, hyperglycemia, metabolic syndrome, acute myocar
dial infarction, hypertension, cardiovascular disease, athero
Sclerosis, peripheral arterial disease, stroke, heart failure,
coronary heart disease, kidney disease, diabetic complica
tions, neuropathy, gastroparesis, disorders associated with
severe inactivating mutations in the insulin receptor, and
other metabolic disorders.

0079. The term “disorders associated with severe inacti
Vating mutations in the insulin receptor, and terms similarly
used herein, describe conditions in subjects afflicted with
mutations in the insulin receptor (or possible proteins directly
downstream from it) which cause severe insulin resistance but
are often (though not always) seen without the obesity com
mon in Type 2 diabetes mellitus. In many ways, Subjects
afflicted with these conditions manifest hybrid symptoms of
Type 1 diabetes mellitus and Type 2 diabetes mellitus. Sub
jects thereby afflicted fall into several categories of roughly
increasing severity, including: Type A Insulin Resistance,
Type C Insulin Resistance (AKA HAIR-AN Syndrome),
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Rabson-Mendenhall Syndrome and finally Donohue's Syn
drome or Leprechaunism. These disorders are associated with
very high endogenous insulin levels, and very often, hyperg
lycemia. Subjects thereby afflicted also present with various
clinical features associated with “insulin toxicity, including
hyperandrogenism, polycystic ovarian syndrome (PCOS),
hirsuitism, and acanthosis nigricans (excessive growth and
pigmentation) in the folds of the skin.
0080 “Type 2 diabetes mellitus' is a condition character
ized by excess glucose production in spite of the availability
of insulin, and circulating glucose levels remain excessively
high as a result of inadequate glucose clearance.
I0081 “Type 1 diabetes mellitus' is a condition character
ized by high blood glucose levels caused by total lack of
insulin. This occurs when the body's immune system attacks
the insulin-producing beta cells in the pancreas and destroys
them. The pancreas then produces little or no insulin.
I0082 “Glucose intolerance' or Impaired Glucose Toler
ance (IGT) is a pre-diabetic state of dysglycemia that is asso
ciated with increased risk of cardiovascular pathology. The
pre-diabetic condition prevents a Subject from moving glu
cose into cells efficiently and utilizing it as an efficient fuel
Source, leading to elevated glucose levels in blood and some
degree of insulin resistance.
I0083) “Hyperglycemia' is defined as an excess of sugar
(glucose) in the blood.
I0084) “Hypoglycemia', also called low blood sugar,
occurs when your blood glucose level drops too low to pro
vide enough energy for your body’s activities.
I0085. “Hyperinsulinemia' is defined as a higher-than-nor
mal level of insulin in the blood.

0086) “Insulin resistance' is defined as a state in which a
normal amount of insulin produces a Subnormal biologic
response.

I0087. “Obesity.” in terms of the human subject, can be
defined as that body weight over 20 percent above the ideal
body weight for a given population (R. H. Williams, Textbook
of Endocrinology, 1974, p. 904-916).
I0088 “Diabetic complications” are problems, caused by
high blood glucose levels, with other body functions such as
kidneys, nerves (neuropathies), feet (foot ulcers and poor
circulation) and eyes (e.g. retinopathies). Diabetes also
increases the risk for heart disease and bone and joint disor
ders. Other long-term complications of diabetes include skin
problems, digestive problems, sexual dysfunction and prob
lems with teeth and gums.
I0089) “Metabolic syndrome” can be defined as a cluster of
at least three of the following signs: abdominal fat—in most
men, a 40-inch waist or greater, high blood Sugar—at least
110 milligrams per deciliter (mg/dl) after fasting; high trig
lycerides—at least 150 mg/dL in the bloodstream; low
HDL less than 40 mg/dl; and, blood pressure of 130/85
mmHg or higher.
0090 “Pancreatitis” is inflammation of the pancreas.
0091 “Dyslipidemia' is a disorder of lipoprotein metabo
lism, including lipoprotein overproduction or deficiency.
Dyslipidemias may be manifested by elevation of the total
cholesterol, low-density lipoprotein (LDL) cholesterol and
triglyceride concentrations, and a decrease in high-density
lipoprotein (HDL) cholesterol concentration in the blood.
0092 “Nonalcoholic fatty liver disease (NAFLD) is a
liver disease, not associated with alcohol consumption, char
acterized by fatty change of hepatocytes.
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0093. “Nonalcoholic steatohepatitis (NASH) is a liver
disease, not associated with alcohol consumption, character
ized by fatty change of hepatocytes, accompanied by intral
obular inflammation and fibrosis.

0094) “Hypertension” or high blood pressure that is a tran
sitory or Sustained elevation of systemic arterial blood pres
Sure to a level likely to induce cardiovascular damage or other
adverse consequences. Hypertension has been arbitrarily
defined as a systolic blood pressure above 140 mmHg or a
diastolic blood pressure above 90 mmHg.
0.095 “Cardiovascular diseases” are diseases related to the
heart or blood vessels.

0096 Acute myocardial infarction’ occurs when there is
interruption of the blood supply to a part of the heart. The
resulting ischemia and oxygen shortage, ifleft untreated for a
Sufficient period of time, can cause damage or death (infarc
tion) of the heart muscle tissue (myocardium).
0097. “Peripheral arterial disease” occurs when plaque
builds up in the arteries that carry blood to the head, organs
and limbs. Over time, plaque can harden and narrow the
arteries which limits the flow of oxygen-rich blood to organs
and other parts of the body.
0.098 Atherosclerosis” is a vascular disease character
ized by irregularly distributed lipid deposits in the intima of
large and medium-sized arteries, causing narrowing of arte
rial lumens and proceeding eventually to fibrosis and calcifi
cation. Lesions are usually focal and progress slowly and
intermittently. Limitation of blood flow accounts for most
clinical manifestations, which vary with the distribution and
severity of lesions.
0099 “Stroke” is any acute clinical event, related to
impairment of cerebral circulation, that lasts longer than 24
hours. A stroke involves irreversible brain damage, the type
and severity of symptoms depending on the location and
extent of brain tissue whose circulation has been compro
mised.

0100 “Heart failure', also called congestive heart failure,
is a condition in which the heart can no longer pump enough
blood to the rest of the body.
0101 “Coronary heart disease', also called coronary
artery disease, is a narrowing of the Small blood vessels that
Supply blood and oxygen to the heart.
0102 “Kidney disease' or nephropathy is any disease of
the kidney. Diabetic nephropathy is a major cause of morbid
ity and mortality in people with type 1 or type 2 diabetes
mellitus.

0103 “Neuroapathies” are any diseases involving the cra
nial nerves or the peripheral or autonomic nervous system.
0104. “Gastroparesis” is weakness of gastric peristalsis,
which results in delayed emptying of the bowels.
0105. The critically ill patients encompassed by the
present invention generally experience an unstable hyper
metabolic state. This unstable metabolic state is due to

changes in Substrate metabolism, which may lead to relative
deficiencies in some nutrients. Generally there is an increased
oxidation of both fat and muscle.

0106 Moreover, critically ill patients are preferably
patients that experience systemic inflammatory response Syn
drome or respiratory distress. A reduction in morbidity means
reducing the likelihood that a critically ill patient will develop
additional illnesses, conditions, or symptoms or reducing the
severity of additional illnesses, conditions, or symptoms. For
example reducing morbidity may correspond to a decrease in
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the incidence of bacteremia or sepsis or complications asso
ciated with multiple organ failure.
0107 As used herein, the singular forms “a” “an and
“the include plural references unless the content clearly
dictates otherwise. Thus, for example, reference to “an anti
body' includes a mixture of two or more such antibodies.
0108. As used herein, the term “about” refers to +/-20%,
more preferably, +/-10%, or still more preferably, +/-5% of
&G

&g

a value.

0109. The terms “polypeptide' and “protein', are used
interchangeably and refer to a polymeric form of amino acids
of any length, which can include coded and non-coded amino
acids, naturally and non-naturally occurring amino acids,
chemically or biochemically modified or derivatized amino
acids, and polypeptides having modified peptide backbones.
The term includes fusion proteins, including, but not limited
to, fusion proteins with a heterologous amino acid sequence,
fusions with heterologous and homologous leader sequences,
with or without N-terminal methionine residues; immuno

logically tagged proteins; and the like.
0110. The terms “individual”, “subject”, “host” and
“patient” are used interchangeably and refer to any subject for
whom diagnosis, treatment, ortherapy is desired, particularly
humans. Other subjects may include cattle, dogs, cats, guinea
pigs, rabbits, rats, mice, horses, and the like. In some pre
ferred embodiments the subject is a human.
0111. As used herein, the term “sample” refers to biologi
cal material from a patient. The sample assayed by the present
invention is not limited to any particular type. Samples
include, as non-limiting examples, single cells, multiple cells,
tissues, tumors, biological fluids, biological molecules, or
Supernatants or extracts of any of the foregoing. Examples
include tissue removed for biopsy, tissue removed during
resection, blood, urine, lymph tissue, lymph fluid, cerebrospi
nal fluid, mucous, and stool samples. The sample used will
vary based on the assay format, the detection method and the
nature of the tumors, tissues, cells or extracts to be assayed.
Methods for preparing samples are well known in the art and
can be readily adapted in order to obtain a sample that is
compatible with the method utilized.
0112. As used herein, the term “biological molecule'
includes, but is not limited to, polypeptides, nucleic acids, and
saccharides.

0113. As used herein, the term “modulating refers to a
change in the quality or quantity of a gene, protein, or any
molecule that is inside, outside, or on the surface of a cell. The

change can be an increase or decrease in expression or level of
the molecule. The term "modulates' also includes changing
the quality or quantity of a biological function/activity includ
ing, without limitation, the ability to lower blood glucose,
insulin, triglyceride, or cholesterol levels; to reduce liver lipid
or liver triglyceride levels; to reduce body weight; and to
improve glucose tolerance, energy expenditure, or insulin
sensitivity.
0114. As used herein, the term “modulator” refers to a
composition that modulates one or more physiological or
biochemical events associated with an FGF21-associated dis

order, such as type 1 or type 2 diabetes mellitus or a metabolic
condition like obesity. Said events include but are not limited
to the ability to lower blood glucose, insulin, triglyceride, or
cholesterol levels; to reduce liver lipid or liver triglyceride
levels; to reduce body weight; and to improve glucose toler
ance, energy expenditure, or insulin sensitivity.
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0115. A “gene product' is a biopolymeric product that is
expressed or produced by a gene. A gene product may be, for
example, an unspliced RNA, an mRNA, a splice variant
mRNA, a polypeptide, a post-translationally modified
polypeptide, a splice variant polypeptide etc. Also encom
passed by this term are biopolymeric products that are made
using an RNA gene product as a template (i.e. cDNA of the
RNA). A gene product may be made enzymatically, recom
binantly, chemically, or within a cell to which the gene is
native. In some embodiments, if the gene product is proteina
ceous, it exhibits a biological activity. In some embodiments,
if the gene product is a nucleic acid, it can be translated into
a proteinaceous gene product that exhibits a biological activ
ity.
0116 “Modulation of FGF21 activity,” as used herein,
refers to an increase or decrease in FGF21 activity that can be
a result of, for example, interaction of an agent with an FGF21
polynucleotide or polypeptide, inhibition of FGF21 tran
Scription and/or translation (e.g., through antisense or siRNA
interaction with the FGF21 gene or FGF21 transcript, through
modulation of transcription factors that facilitate FGF21
expression), and the like. For example, modulation of a bio
logical activity refers to an increase or a decrease in a bio
logical activity. FGF21 activity can be assessed by means
including, without limitation, assaying blood glucose, insu
lin, triglyceride, or cholesterol levels in a subject, assessing
FGF21 polypeptide levels, or by assessing FGF21 transcrip
tion levels. Comparisons of FGF21 activity can also be
accomplished by, e.g., measuring levels of an FGF21 down
stream biomarker, and measuring increases in FGF21 signal
ing. FGF21 activity can also be assessed by measuring: cell
signaling; kinase activity; glucose uptake into adipocytes;
blood insulin, triglyceride, or cholesterol level fluctuations:
liver lipid or liver triglyceride level changes; interactions
between FGF21 and an FGF21 receptor; or phosphorylation
ofan FGF21 receptor. In some embodiments phosphorylation
of an FGF21 receptor can be tyrosine phosphorylation. In
some embodiments modulation of FGF21 activity can cause
modulation of an FGF21-related phenotype.
0117 Comparisons of FGF21 activity can also be accom
plished by, e.g., measuring levels of an FGF21 downstream
biomarker, and measuring increases in FGF21 signaling.
FGF21 activity can also be assessed by measuring: cell sig
naling; kinase activity; glucose uptake into adipocytes; blood
insulin, triglyceride, or cholesterol level fluctuations; liver
lipid or liver triglyceride level changes; interactions between
FGF21 and a receptor (FGFR-1c, FGFR-2c, or FGFR-3c); or
phosphorylation of an FGF21 receptor. In some embodiments
phosphorylation of an FGF21 receptor can be tyrosine phos
phorylation. In some embodiments modulation of FGF21
activity can cause modulation of an FGF21-related pheno
type.

0118 A“FGF21 downstream biomarker” as used herein,
is a gene or gene product, or measurable indicia of a gene or
gene product. In some embodiments, a gene or activity that is
a downstream marker of FGF21 exhibits an altered level of

expression, or in a vascular tissue. In some embodiments, an
activity of the downstream marker is altered in the presence of
an FGF21 modulator. In some embodiments, the downstream

markers exhibit altered levels of expression when FGF21 is
perturbed with an FGF21 modulator of the present invention.
FGF21 downstream markers include, without limitation, glu
cose or 2-deoxy-glucose uptake, pERK and other phospho
rylated or acetylated proteins or NAD levels.
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0119. As used herein, the term "up-regulates’ refers to an
increase, activation or stimulation of an activity or quantity.
For example, in the context of the present invention, FGF21
modulators may increase the activity of an FGF21 receptor. In
one embodiment, one or more FGFR-1c, FGFR-2c, or FGFR

3c may be upregulated in response to an FGF21 modulator.
Upregulation can also refer to an FGF21-related activity, such
as e.g., the ability to lower blood glucose, insulin, triglycer
ide, or cholesterol levels; to reduce liver lipid or triglyceride
levels; to reduce body weight; to improve glucose tolerance,
energy expenditure, or insulin sensitivity; or to cause phos
phorylation of an FGF21 receptor; or to increase an FGF21
downstream marker. The FGFR21 receptor can be one or
more of FGFR-1c, FGFR-2c, or FGFR-3c. Up-regulation
may beat least 25%, at least 50%, at least 75%, at least 100%,
at least 150%, at least 200%, at least 250%, at least 400%, or

at least 500% as compared to a control.
0.120. As used herein, the term “N-terminus’ refers to at
least the first 20 amino acids of a protein.
0.121. As used herein, the terms “N-terminal domain and
“N-terminal region' are used interchangeably and refer to a
fragment of a protein that begins at the first amino acid of the
protein and ends at any amino acid in the N-terminal half of
the protein. For example, the N-terminal domain of FGF21 is
from amino acid 1 of SEQ ID NO:1 to any amino acid
between about amino acids 10 and 105 of SEQID NO:1.
0.122. As used herein, the term “C-terminus’ refers to at
least the last 20 amino acids of a protein.
(0123. As used herein, the terms “C-terminal domain” and
“C-terminal region' are used interchangeably and refer to a
fragment of a protein that begins at any amino acid in the
C-terminal half of the protein and ends at the last amino acid
of the protein. For example, the C-terminal domain of FGF21
begins at any amino acid from amino acid 105 to about amino
acid 200 of SEQID NO:1 and ends atamino acid 209 of SEQ
ID NO:1.

0.124. The term “domain” as used herein refers to a struc
tural part of a biomolecule that contributes to a known or
Suspected function of the biomolecule. Domains may be co
extensive with regions orportions thereofand may also incor
porate a portion of a biomolecule that is distinct from a
particular region, in addition to all or part of that region.
0.125. As used herein, the term “signal domain (also
called 'signal sequence' or 'signal peptide') refers to a pep
tide domain that resides in a continuous stretch of amino acid

sequence at the N-terminal region of a precursor protein
(often a membrane-bound or secreted protein) and is involved
in post-translational protein transport. In many cases the sig
nal domain is removed from the full-length protein by spe
cialized signal peptidases after the sorting process has been
completed. Each signal domain specifies a particular destina
tion in the cell for the precursor protein. The signal domain of
FGF21 is amino acids 1-28 of SEQID NO:1.
I0126. As used herein, the term “receptor binding domain
refers to any portion or region of a protein that contacts a
membrane-bound receptor protein, resulting in a cellular
response, Such as a signaling event.
I0127. As used herein, the term “ligand binding domain
refers to any portion or region of a fusion protein of the
invention retaining at least one qualitative binding activity of
a corresponding native sequence.
I0128. The term “region” refers to a physically contiguous
portion of the primary structure of a biomolecule. In the case
of proteins, a region is defined by a contiguous portion of the
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amino acid sequence of that protein. In some embodiments a
“region' is associated with a function of the biomolecule.
0129. The term “fragment as used herein refers to a
physically contiguous portion of the primary structure of a
biomolecule. In the case of proteins, a portion is defined by a
contiguous portion of the amino acid sequence of that protein
and refers to at least 3-5 amino acids, at least 8-10 amino
acids, at least 11-15 amino acids, at least 17-24 amino acids,
at least 25-30 amino acids, and at least 30-45 amino acids. In

the case of oligonucleotides, a portion is defined by a con
tiguous portion of the nucleic acid sequence of that oligo
nucleotide and refers to at least 9-15 nucleotides, at least
18-30 nucleotides, at least 33-45 nucleotides, at least 48-72
nucleotides, at least 75-90 nucleotides, and at least 90-130

nucleotides. In some embodiments, portions of biomolecules
have a biological activity. In the context of the present inven
tion, FGF21 polypeptide fragments do not comprise the entire
FGF21 polypeptide sequence set forth in SEQID NO:1.
0130. A “native sequence' polypeptide is one that has the
same amino acid sequence as a polypeptide derived from
nature. Such native sequence polypeptides can be isolated
from nature or can be produced by recombinant or synthetic
means. Thus, a native sequence polypeptide can have the
amino acid sequence of naturally occurring human polypep
tide, murine polypeptide, or polypeptide from any other
mammalian species.
0131. As used herein, the phrase “homologous nucleotide
sequence.” or “homologous amino acid sequence.” or varia
tions thereof, refers to sequences characterized by a homol
ogy, at the nucleotide level or amino acid level, of at least a
specified percentage and is used interchangeably with
"sequence identity.” Homologous nucleotide sequences
include those sequences coding for isoforms of proteins. Such
isoforms can be expressed in different tissues of the same
organism as a result of for example, alternative splicing of
RNA. Alternatively, isoforms can be encoded by different
genes. Homologous nucleotide sequences include nucleotide
sequences encoding for a protein of a species other than
humans, including, but not limited to, mammals. Homolo
gous nucleotide sequences also include, but are not limited to,
naturally occurring allelic variations and mutations of the
nucleotide sequences set forth herein. Homologous amino
acid sequences include those amino acid sequences which
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nucleotides that are at least about 95%, about 97%, about

98%, about 99% and about 100% homologous to SEQ ID
NO:2, or a portion thereof.
0.133 Homology may also be at the polypeptide level. In
Some embodiments, constituent polypeptides of the fusion
proteins of the invention may be at least 95% homologous to
their full length wild-type counterparts or corresponding
native sequences, or to portions thereof. The degree or per
centage identity of Fusion Proteins of the invention, or por
tions thereof, and different amino acid sequences is calcu
lated as the number of exact matches in an alignment of the
two sequences divided by the length of the “invention
sequence' or the “foreign sequence', whichever is shortest.
The result is expressed as percent identity.
I0134. As used herein, the term “mixing refers to the
process of combining one or more compounds, cells, mol
ecules, and the like together in the same area. This may be
performed, for example, in a test tube, petri dish, or any
container that allows the one or more compounds, cells, or
molecules, to be mixed.

I0135. As used herein, the term “substantially purified’
refers to a compound (e.g., either a polynucleotide or a
polypeptide or an antibody) that is removed from its natural
environment and is at least 60% free, at least 75% free, and at

least 90% free from other components with which it is natu
rally associated.
0.136 The term “pharmaceutically acceptable carrier'
refers to a carrier for administration of a therapeutic agent,
such as antibodies or a polypeptide, genes, and other thera
peutic agents. The term refers to any pharmaceutical carrier
that does not itself induce the production of antibodies harm
ful to the individual receiving the composition, and which can
be administered without undue toxicity. Suitable carriers can
be large, slowly metabolized macromolecules such as pro
teins, polysaccharides, polylactic acids, polyglycolic acids,
polymeric amino acids, amino acid copolymers, lipid aggre
gates and inactive virus particles. Such carriers are well
known to those of ordinary skill in the art. Pharmaceutically
acceptable carriers in therapeutic compositions can include
liquids Such as water, saline, glycerol and ethanol. Auxiliary
Substances, such as wetting or emulsifying agents, pH buff
ering Substances, and the like, can also be present in Such
vehicles.

Enhancing the Physical Stability of the Fusion Proteins of the

contain conservative amino acid Substitutions and which

Invention

polypeptides have the same binding and/or activity. In some
embodiments, a nucleotide or amino acid sequence is
homologous if it has at least 60% or greater, up to 99%,
identity with a comparator sequence. In some embodiments,
a nucleotide or amino acid sequence is homologous if it
shares one or more, up to 60, nucleotide?amino acid Substi
tutions, additions, or deletions with a comparator sequence.
In some embodiments, the homologous amino acid
sequences have no more than 5 or no more than 3 conservative

0.137 Naturally occurring disulfide bonds, as provided by
cysteine residues, generally increase thermodynamic stabil
ity of proteins. Successful examples of increased thermody
namic stability, as measured in increase of the melting tem
perature, are multiple disulfide-bonded mutants of the
enzymes T4 lysozyme (Matsumuraet al., PNAS 86:6562
6566 (1989)) and barnase (Johnson et al., J. Mol. Biol. 268:
198-208 (1997)). An aspect of the present invention is an
enhancement of the physical stability of FGF21 in the pres
ence of a preservative, achieved by the presence of disulfide
bonds within the variants, which constrain the flexibility of
wild-type FGF21 and thereby limit access of the preservative
to the hydrophobic core of the protein.
0.138. The second aspect of the present invention therefore
provides variants of human FGF21, or a biologically active
peptide thereof, with enhanced pharmaceutical stability
engendered by the incorporation of additional disulfide
bonds, e.g., via incorporating or substituting cysteine resi

amino acid Substitutions.

0132) Percent homology or identity can be determined by,
for example, the Gap program (Wisconsin Sequence Analysis
Package, Version 8 for UNIX, Genetics Computer Group,
University Research Park, Madison Wis.), using default set
tings, which uses the algorithm of Smith and Waterman (Adv.
Appl. Math., 1981, 2, 482-489). In some embodiments,
homology between the probe and target is between about 75%
to about 85%. In some embodiments, nucleic acids have
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Alal62Cys, Thr57Cys-Ala162Cys, Glu58Cys-Ala162Cys,
Arg47Cys-Arg163Cys, Tyr18Cys-Arg163Cys, Leu49Cys
Arg163Cys, TyrSOCys-Arg163Cys, Thr51Cys-Arg163Cys,
Asp52Cys-Arg163Cys, Asp53Cys-Arg163Cys, Alaš4Cys
Arg163Cys, Gln55Cys-Arg163Cys, Gln56Cys-Arg163Cys,
Thr57Cys-Arg163Cys, Glu58Cys-Arg163Cys
0141 Another aspect of the present invention provides
fusion proteins comprising variants of wild-type human
FGF21, or a biologically active peptide thereof, comprising a
Substitution of any charged and/or polar but uncharged amino
acid at any of the amino acid positions indicated in the first
embodiment of the present invention combined with the sub
stitution of a cysteine at two or more amino acid positions
indicated in the second embodiment of the invention.

Improvements of the Fusion Proteins of the Invention Over
Wild Type Protein Comparators and Variants. Thereof
0142. It is well known in the art that a significant challenge
in the development of protein pharmaceuticals is to deal with
the physical and chemical instabilities of proteins. This is
even more apparent when a protein pharmaceutical formula
tion is intended to be a multiple use, injectable formulation
requiring a stable, concentrated and preserved solution, while
maintaining a favorable bioactivity profile. Biophysical char
acterization of wild-type FGF21 in the literature established
that a concentrated protein solution (>5 mg/ml), when
exposed to stress conditions, such as high temperature or low
pH, lead to accelerated association and aggregation (i.e., poor
physical stability and biopharmaceutical properties). Expo
sure of a concentrated protein solution of FGF21 to pharma
ceutical preservatives (e.g., m-cresol) also had a negative
impact on physical stability.
0143. Therefore, an embodiment of the present invention
is to enhance physical stability of concentrated Solutions,
while maintaining chemical stability and biological potency,
under both physiological and preserved formulation condi
tions. It is thought that association and aggregation may result
from hydrophobic interactions, since, at a given protein con
centration, temperature, and ionic strength have considerable
impact on physical stability. For the most part, non-con
served, presumed Surface exposed amino acid residues were
targeted. The local environment of these residues was ana
lyzed and, those that were not deemed structurally important
were selected for mutagenesis. One method to initiate specific
changes is to further decrease the pi of the protein by intro
ducing glutamic acid residues (glutamic acid scan). It is
hypothesized that the introduction of charged substitutes
would inhibit hydrophobic-mediated aggregation via charge
charge repulsion and potentially improve preservative com
patibility. In addition, one skilled in the art would also recog
nize that with sufficient degree of mutagenesis the p could be
shifted into a basic pH range by the introduction of positive
charge with or without concomitant decrease in negative
charge, thus allowing for charge-charge repulsion.
0144. An additional difficulty associated with therapeutic
applications of wild-type FGF21 as a biotherapeutic, for
instance, is that its half-life is very short in vivo (on the order
of 0.5 and 2 h, respectively, in mouse and primate). There is
hence a need to develop follow-up compounds that are more
efficacious either through higher potency or longer half-life.
The fusion proteins of the invention were developed as a way
to achieve the desirable effects of FGF21 treatmentata higher
potency and in a half-life-extended formulation.

0145 As described further herein, the fusion proteins of
the invention have half-lives of greater than two weeks in the
mouse, compared to the much shorter half-life of wild-type
FGF21 and the 17 hour half-life of fusion protein Fc-L(15)FGF21 (L98R, P171G, A180E) in PCT Publication WO10/
129,600. The fusion proteins of the invention also demon
strate improved half-life and pharmacokinetic properties
compared to PEGylated V76, as described herein and in U.S.
patent application 61/415,476, filed on Nov. 19, 2010.
0146). Furthermore, the Fc-FGF21 fusion proteins of the
invention at 1 mpk are more efficacious than V76 at 5 mpk on
reducing glucose, insulin, body weight and liver lipid. In a
12-day treatment study in ob/ob mice, the fusion proteins
show the following % changes from vehicle (all of the fusions
are administered at 1.0 mg/kg, and V76 is administered at 5.0
mg/kg):
0147 Total glucose (AUC)% change from vehicle:V76 is
-42%; V101 is -53%, V103 is -46%, and V188 is -42%;

0.148. Total plasma insulin 96 change from vehicle: V76 is
-46%; V101 is -82%, V103 is -69%, and V188 is -59%;

0149 Total body weight % change from vehicle: V76 is
-7%; V101 is -12%, V103 is -12%, and V188 is -1.1%; and

(O150 Total liver lipid % change from vehicle: V76 is
-30%; V101 is -44%, V103 is -50%, and V188 is -51%.

0151. Similarly, in vitro assays reveal the same 5-fold or
greater potency of the fusion proteins of the invention over
V76:

0152. In the pERK in human adipocytes assay (mean
EC50+SEM), V76 is 21+2 nM (n=3); V101 is 1.0+0.1 nM
(n=3), V103 is 1.3+0.2 nM (n=3), and V188 is 1.4+0.4 nM
(n-3);
0153. In the pERK in HEK293 with human Bklotho assay
(mean EC50+SEM), V76 is 13+4 nM (n=5), V101 is 0.60+0.
06 nM (n=5), V103 is 0.9-0.3 nM (n=5), and V188 is 0.4+0.1
nM (n=3); and
0154 In the glucose uptake in mouse adipocytes assay
(mean EC50+SEM), V76 is 5+1 nM (n-3), V101 is 0.60+0.06
nM (n=3), V103 is 0.60+0.07 nM (n=3), and V188 is 0.48+0.
14 nM (n=3).
0155 Although the embodiments of the present invention
concern the physical and chemical stability under both physi
ological and preserved pharmaceutical formulation condi
tions, maintaining the biological potency of the fusion pro
teins of the invention as compared to, e.g., wild-type FGF21
is an important factor of consideration as well. Therefore, the
biological potency of the proteins of the present invention is
defined by the ability of the proteins to affect glucose uptake
and/or the lowering of plasma glucose levels, as shown herein
in the examples.
0156 The proteins, polypeptides, and/or peptides of the
invention administered according to this invention may be
generated and/or isolated by any means known in the art. The
most preferred method for producing the variant is through
recombinant DNA methodologies and is well known to those
skilled in the art. Such methods are described in Current

Protocols in Molecular Biology (John Wiley & Sons, Inc.),
which is incorporated herein by reference.
0157 Additionally, the preferred embodiments include a
biologically active peptide derived from the variant described
herein. Such a peptide will contain at least one of the substi
tutions described and the variant will possess biological activ
ity. The peptide may be produced by any and all means known
to those skilled in the art, examples of which included but are
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not limited to enzymatic digestion, chemical synthesis or
recombinant DNA methodologies.
0158. It is established in the art that fragments of peptides
of certain fibroblast growth factors are biologically active.
See for example, Baird et al., Proc. Natl. Acad. Sci. (USA)
85:2324-2328 (1988), and J. Cell. Phys. Suppl. 5:101-106
(1987). Therefore, the selection of fragments or peptides of
the variant is based on criteria known in the art. For example,
it is known that dipeptidyl peptidase IV (DPP-IV, or DPP-4)
is a serine type protease involved in inactivation of neuropep
tides, endocrine peptides, and cytokines (Damme etal. Chem.
Immunol. 72: 42-56, (1999)). The N-terminus of FGF21
(HisProllePro) contains two dipeptides that could potentially
be substrates to DPP-IV, resulting in a fragment of FGF21
truncated at the N-terminus by 4 amino acids. Unexpectedly,
this fragment of wild-type FGF21 has been demonstrated to
retain biological activity, thus, proteins of the present inven
tion truncated at the N-terminus by up to 4 amino acids, is an
embodiment of the present invention.
0159. The invention also encompasses polynucleotides
encoding the above-described variants that may be in the
form of RNA or in the form of DNA, which DNA includes

cDNA, genomic DNA, and synthetic DNA. The DNA may be
double-stranded or single-stranded. The coding sequences
that encode the proteins of the present invention may vary as
a result of the redundancy or degeneracy of the genetic code.
0160 The polynucleotides that encode for the fusion pro
teins of the invention may include the following: only the
coding sequence for the variant, the coding sequence for the
variant and additional coding sequence Such as a functional
polypeptide, or a leader or secretory sequence or a pro-protein
sequence; the coding sequence for the variant and non-coding
sequence. Such as introns or non-coding sequence 5' and/or 3'
of the coding sequence for the variant. Thus the term “poly
nucleotide encoding a variant' encompasses a polynucleotide
that may include not only coding sequence for the variant but
also a polynucleotide, which includes additional coding and/
or non-coding sequence.
0161 The invention further relates to variants of the
described polynucleotides that encode for fragments, analogs
and derivatives of the polypeptide that contain the indicated
substitutions. The variant of the polynucleotide may be a
naturally occurring allelic variant of the human FGF21
sequence, a non-naturally occurring variant, or a truncated
variant as described above. Thus, the present invention also
includes polynucleotides encoding the variants described
above, as well as variants of Such polynucleotides, which
variants encode for a fragment, derivative or analog of the
disclosed variant. Such nucleotide variants include deletion

variants, Substitution variants, truncated variants, and addi

tion or insertion variants as long as at least one of the indicated
amino acid Substitutions of the first or second embodiments is

present.

0162 The polynucleotides of the invention will be
expressed in hosts after the sequences have been operably
linked to (i.e., positioned to ensure the functioning of) an
expression control sequence. These expression vectors are
typically replicable in the host organisms either as episomes
or as an integral part of the host chromosomal DNA. Com
monly, expression vectors will contain selection markers,
e.g., tetracycline, neomycin, and dihydrofolate reductase, to
permit detection of those cells transformed with the desired
DNA sequences. The FGF21 variant can be expressed in
mammalian cells, insect, yeast, bacterial or other cells under
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the control of appropriate promoters. Cell free translation
systems can also be employed to produce Such proteins using
RNAs derived from DNA constructs of the present invention.
0163 E. coli is a prokaryotic host useful particularly for
cloning the polynucleotides of the present invention. Other
microbial hosts suitable for use include Bacillus subtilus,

Salmonella typhimurium, and various species of Serratia,
Pseudomonas, Streptococcus, and Staphylococcus, although
others may also be employed as a matter of choice. In these
prokaryotic hosts, one can also make expression vectors,
which will typically contain expression control sequences
compatible with the host cell (e.g., an origin of replication). In
addition, any of a number of well-known promoters may be
present, such as the lactose promoter system, a tryptophan
(Trp) promoter system, a beta-lactamase promoter system, or
a promoter system from phages lambda or T7. The promoters
will typically control expression, optionally with an operator
sequence, and have ribosome binding site sequences and the
like, for initiating and completing transcription and transla
tion.

0164. One skilled in the art of expression of proteins will
recognize that methionine or methionine-arginine sequence
can be introduced at the N-terminus of the mature sequence
(SEQ ID NO: 3) for expression in E. coli and are contem
plated within the context of this invention. Thus, unless oth
erwise noted, proteins of the present invention expressed in E.
coli have a methionine sequence introduced at the N-termi
US

0.165. Other microbes, such as yeast or fungi, may also be
used for expression. Pichia pastoris, Saccharomyces cerevi
siae, Schizosaccharomyces pombe, and Pichia angusta are
examples of preferred yeast hosts, with suitable vectors hav
ing expression control sequences. Such as promoters, includ
ing 3-phosphoglycerate kinase or other glycolytic enzymes,
and an origin of replication, termination sequences and the
like as desired. Aspergillus niger; Trichoderma reesei; and
Schizophyllum commune, are examples of fungi hosts,
although others may also be employed as a matter of choice.
0166 Mammalian tissue cell culture may also be used to
express and produce the polypeptides of the present inven
tion. Eukaryotic cells are actually preferred, because a num
ber of suitable host cell lines capable of secreting intact vari
ants have been developed in the art, and include the CHO cell
lines, various COS cell lines, NSO cells, Syrian Hamster
Ovary cell lines, HeLa cells, or human embryonic kidney cell
lines (i.e. HEK293, HEK293EBNA).
0.167 Expression vectors for these cells can include
expression control sequences, such as an origin of replication,
a promoter, an enhancer, and necessary processing informa
tion sites, such as ribosome binding sites, RNA splice sites,
polyadenylation sites, and transcriptional terminator
sequences. Preferred expression control sequences are pro
moters derived from SV40, adenovirus, bovine papilloma
virus, cytomegalovirus, Raus sarcoma virus, and the like.
Preferred polyadenylation sites include sequences derived
from SV40 and bovine growth hormone.
0.168. The vectors containing the polynucleotide
sequences of interest (e.g., the fusion proteins of the invention
and expression control sequences) can be transferred into the
host cell by well-known methods, which vary depending on
the type of cellular host. For example, calcium chloride trans
fection is commonly utilized for prokaryotic cells, whereas
calcium phosphate treatment or electroporation may be used
for other cellular hosts.
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0169. Various methods of protein purification may be
employed and Such methods are known in the art and
described, for example, in Deutscher, Methods in Enzymol
ogy 182: 83-9 (1990) and Scopes, Protein Purification: Prin
ciples and Practice, Springer-Verlag, NY (1982). The purifi
cation step(s) selected will depend, for example, on the nature
of the production process used for the fusion proteins of the
invention.

0170 The proteins, polypeptides, and/or peptides of the
invention, e.g., the dual activity fusion proteins of the inven
tion, should be formulated and dosed in a fashion consistent

with good medical practice, taking into account the clinical
condition of the patient, the site of delivery of the protein
compositions, the method of administration, the scheduling
of administration, and other factors known to practitioners.
The “therapeutically effective amount of the fusion proteins
of the invention for purposes herein is thus determined by
Such considerations.

0171 The pharmaceutical compositions of the proteins of
the present invention may be administered by any means that
achieve the generally intended purpose: to treat type 1 and
type 2 diabetes mellitus, obesity, metabolic syndrome, or
critically ill patients. Non-limiting permissible means of
administration include, for example, by inhalation or Sup
pository or to mucosal tissue such as by lavage to vaginal,
rectal, urethral, buccal and Sublingual tissue, orally, nasally,
topically, intranasally, intraperitoneally, parenterally, intrave
nously, intramuscularly, intrasternally, by intraarticular injec
tion, intralymphatically, interstitially, intra-arterially, subcu
taneously, intrasynovial, transepithelial, and transdermally.
In some embodiments, the pharmaceutical compositions are
administered by lavage, orally or inter-arterially. Other suit
able methods of introduction can also include rechargeable or
biodegradable devices and slow or Sustained release poly
meric devices. The pharmaceutical compositions of this
invention can also be administered as part of a combinatorial
therapy with other known metabolic agents.
0172. The dosage administered will be dependent upon
the age, health, and weight of the recipient, kind of concurrent
treatment, ifany, frequency of treatment, and the nature of the
effect desired. Compositions within the scope of the invention
include all compositions whereinan FGF21 variant is present
in an amount that is effective to achieve the desired medical

effect for treatment type 1 or type 2 diabetes mellitus, obesity,
or metabolic syndrome. While individual needs may vary
from one patient to another, the determination of the optimal
ranges of effective amounts of all of the components is within
the ability of the clinician of ordinary skill.
0173 The proteins of the present invention can be formu
lated according to known methods to prepare pharmaceuti
cally useful compositions. A desired formulation would be
one that is a stable lyophilized product that is reconstituted
with an appropriate diluent or an aqueous solution of high
purity with optional pharmaceutically acceptable carriers,
preservatives, excipients or stabilizers Remington’s Phar
maceutical Sciences 16th edition (1980). The proteins of the
present invention may be combined with a pharmaceutically
acceptable buffer, and the pH adjusted to provide acceptable
stability, and a pH acceptable for administration.
0.174 For parenteral administration, in one embodiment,
the fusion proteins of the invention are formulated generally
by mixing one or more of them at the desired degree of purity,
in a unit dosage injectable form (solution, Suspension, or
emulsion), with a pharmaceutically acceptable carrier, i.e.,
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one that is non-toxic to recipients at the dosages and concen
trations employed and is compatible with other ingredients of
the formulation. Preferably, one or more pharmaceutically
acceptable anti-microbial agents may be added. Phenol,
m-cresol, and benzyl alcohol are preferred pharmaceutically
acceptable anti-microbial agents.
0.175 Optionally, one or more pharmaceutically accept
able salts may be added to adjust the ionic strength or tonicity.
One or more excipients may be added to further adjust the
isotonicity of the formulation. Glycerin, sodium chloride, and
mannitol are examples of an isotonicity adjusting excipient.
0176 Those skilled in the art can readily optimize phar
maceutically effective dosages and administration regimens
for therapeutic compositions comprising Proteins of the
invention, as determined by good medical practice and the
clinical condition of the individual patient. A typical dose
range for the proteins of the present invention will range from
about 0.01 mg per day to about 1000 mg per day (or about
0.05 mg per week to about 5000 mg per week administered
once per week) for an adult. Preferably, the dosage ranges
from about 0.1 mg per day to about 100 mg per day (or about
0.5 mg per week to about 500 mg per week administered once
per week), more preferably from about 1.0 mg/day to about
10 mg/day (or about 5 mg per week to about 50 mg per week
administered once per week). Most preferably, the dosage is
about 1-5 ring/day (or about 5 mg per week to about 25 mg per
week administered once per week). The appropriate dose of
an FGF21 variant administered will result in lowering blood
glucose levels and increasing energy expenditure by faster
and more efficient glucose utilization, and thus is useful for
treating type 1 and type 2 diabetes mellitus, obesity and
metabolic syndrome.
0177. In addition, because hyperglycemia and insulin
resistance are common in critically ill patients given nutri
tional Support, Some ICUs administer insulin to treat exces
sive hyperglycemia in fed critically ill patients. In fact, recent
studies document the use of exogenous insulin to maintain
blood glucose at a level no higher than 110 mg per deciliter
reduced morbidity and mortality among critically ill patients
in the Surgical intensive care unit, regardless of whether they
had a history of diabetes (Van den Bergheet al. N Engl J.
Med., 345(19): 1359, (2001)). Thus, proteins of the present
invention are uniquely suited to help restore metabolic stabil
ity in metabolically unstable critically ill patients. Proteins of
the invention such as those containing variants of FGF21 are
unique in that they stimulate glucose uptake and enhances
insulin sensitivity but do not induce hypoglycemia.
0178. In another aspect of the present invention, proteins
of the invention for use as a medicament for the treatment of

obesity, type 1 and type 2 diabetes mellitus, pancreatitis,
dyslipidemia, nonalcoholic fatty liver disease (NAFLD),
nonalcoholic steatohepatitis (NASH), insulin resistance,
hyperinsulinemia, glucose intolerance, hyperglycemia, meta
bolic syndrome, acute myocardial infarction, conditions
associated with severe inactivating mutations in the insulin
receptor, and other metabolic disorders is contemplated.
Site-Specific FGF21 Mutants
0179. In some embodiments, the fusion proteins of the
invention include additional FGF21 mutants or FGF21 ana

logues with unnatural amino acids.
0180. In some embodiments, the fusion proteins of the
invention comprise FGF21 agonists with one or more of the
following additional modifications of wild-type FGF21:
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0181 (i) additional disulfides, unnatural amino acids, or
modifications to promote dimerization such as formation of a
disulfide at R154C or introduction of a cysteine at another
site, or dimerization through a fused Fc domain, or dimer
formation through a cross-linker such as a bifunctional PEG:
0182 (ii) fragments of FGF21;
0183 (ii) proteins selected to have FGF21 activity (bind
ing to beta-klotho and binding and activation of the FGFRs);
and

0184 (iv) an FGF21 mimetic antibody (of various formats
such as Fab, unibody, SvFc etc.).
0185. In some embodiments, the fusion proteins of the
invention comprise one or more of the following linkers: a
simple amide bond, short peptides (particularly Ser/Gly
repeats), additional residues from the FGF21 translated
sequence, or a larger linker up to an entire protein (such as an
Fc domain, an HSA-binding helix bundle, HSA, etc.).
0186 The two moieties can also be linked by other chemi
cal means, such as through unnatural amino acids or standard
chemical linkers (maleimide-Cys, NHS-Lys, click, etc.)
0187. Other embodiments of the invention include but are
not limited to the following attachments, for half-life exten
sion: HSA-binding lipid or small molecule or micelle to
either the monomeric or a dimeric version of the fusion.

0188 In certain embodiments of the invention, other
attachments may be made to proteins, polypeptides, and/or
peptides of the invention, to achieve half-life extension and
other improved biological properties. They can include
attaching PEG-cholesterol conjugates (including micelles
and liposomes) to the proteins, polypeptides, and/or peptides
of the invention, and/or attaching Sugars (glycosylate) to the
proteins, polypeptides, and/or peptides of the invention. In
still other embodiments, similar techniques are employed to
add conjugates of, e.g., polysialic acid (PSA), hydroxyethyl
starch (HES), albumin-binding ligands, or carbohydrate
shields to proteins, polypeptides, and/or peptides.
0189 The HESylation technique, for example, couples
branched hydroxyethylstarch (HES) chains (60 kDa or 100
kDa, highly branched amylopectin fragments from corn
starch) to a protein, polypeptides, and/or peptides via reduc
tive alkylation. Polsialation conjugates proteins, polypep
tides, and/or peptides of interest with polysialic acid (PSA)
polymers in a manner similar to PEGylation. PSA polymers
are negatively charged, non-immunogenic polymers that
occur naturally in the body and are available in molecular
weights of 10-50 kD.
0190. In still other embodiments of the invention, other
attachments or modifications may be made to proteins,
polypeptides, and/or peptides of the invention, to achieve
half-life extension and other improved biological properties.
These include the creation of recombinant PEG (rPEG)
groups, and their attachment to the proteins, polypeptides,
and/or peptides of the invention. As developed by the com
pany Amunix, Inc. The rPEG technology is based on protein
sequences with PEG-like properties that are genetically fused
to biopharmaceuticals, avoiding the extra chemical conjuga
tion step. rPEGs are extended half-life exenatide constructs
that contain a long unstructured tail of hydrophilic amino
acids, and which are capable of both increasing a protein or
peptide's serum half-life and slowing its rate of absorption,
thus reducing the peak-trough ratio significantly. rPEGs have
an increased hydrodynamic radius and show an apparent
molecular weight that is about 15-fold their actual molecular
weight, mimicking the way PEGylation achieves a long
serum half-life.
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Truncated FGF21 Polypeptides
0191) One embodiment of the present invention is directed
to truncated forms of the mature FGF21 polypeptide (SEQID
NO:3). This embodiment of the present invention arose from
an effort to identify truncated FGF21 polypeptides that are
capable of providing an activity that is similar, and in some
instances superior, to untruncated forms of the mature FGF21
polypeptide.
(0192. As used herein, the term “truncated FGF21
polypeptide' refers to an FGF21 polypeptide in which amino
acid residues have been removed from the amino-terminal (or
N-terminal) end of the FGF21 polypeptide, amino acid resi
dues have been removed from the carboxyl-terminal (or
C-terminal) end of the FGF21 polypeptide, or amino acid
residues have been removed from both the amino-terminal

and carboxyl-terminal ends of the FGF21 polypeptide. The
various truncations disclosed herein were prepared as
described herein.

(0193 The activity of N-terminally truncated FGF21
polypeptides and C-terminally truncated FGF21 polypep
tides can be assayed using an in vitro phospho-ERK assay.
Specific details of the in vitro assays that can be used to
examine the activity of truncated FGF21 polypeptides can be
found in the examples.
(0194 The activity of the truncated FGF21 polypeptides of
the present invention can also be assessed in an in vivo assay,
such as ob/ob mice. Generally, to assess the in vivo activity of
a truncated FGF21 polypeptide, the truncated FGF21
polypeptide can be administered to a test animal intraperito
neally. After a desired incubation period (e.g., one hour or
more), a blood sample can be drawn, and blood glucose levels
can be measured.

(0195 a.N-Terminal Truncations
0196. In some embodiments of the present invention,
N-terminal truncations comprise 1, 2, 3, 4, 5, 6, 7, or 8 amino
acid residues from the N-terminal end of the mature FGF21

polypeptide. Truncated FGF21 polypeptides having N-termi
nal truncations offewer than 9 amino acid residues retain the

ability of the mature FGF21 polypeptide to lower blood glu
cose in an individual. Accordingly, in particular embodi
ments, the present invention encompasses truncated forms of
the mature FGF21 polypeptide or FGF21 protein variants
having N-terminal truncations of 1,2,3,4, 5, 6, 7, or 8 amino
acid residues.

0.197 b. C-Terminal Truncations
0.198. In some embodiments of the present invention,
C-terminal truncations comprise 1,2,3,4,5,6,7,8,9, 10, 11,
or 12 amino acid residues from the C-terminal end of the

mature FGF21 polypeptide. Truncated FGF21 polypeptides
having C-terminal truncations of fewer than 13 amino acid
residues exhibited an efficacy of at least 50% of the efficacy of
wild-type FGF21 in an in vitro ELK-luciferase assay (Yie J. et
al. FEBS Letts 583:19-24 (2009)), indicating that these
FGF21 mutants retain the ability of the mature FGF21
polypeptide to lower blood glucose in an individual. Accord
ingly, in particular embodiments, the present invention
encompasses truncated forms of the mature FGF21 polypep
tide or FGF21 protein variants having C-terminal truncations
of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues.
(0199 c. N-Terminal and C-Terminal Truncations

0200. In some embodiments of the present invention, trun
cated FGF21 polypeptides can have a combination of N-ter
minal and C-terminal truncations. Truncated FGF21

polypeptides having a combination of N-terminal and C-ter
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minal truncations share the activity of corresponding trun
cated FGF21 polypeptides having either the N-terminal or
C-terminal truncations alone. In other words, truncated

FGF21 polypeptides having both N-terminal truncations of
fewer than 9 amino acid residues and C-terminal truncations

of fewer than 13 amino acid residues possess similar or
greater blood glucose-lowering activity as truncated FGF21
polypeptides having N-terminal truncations of fewer than 9
amino acid residues or truncated FGF21 polypeptides having
C-terminal truncations offewer than 13 amino acid residues.

Accordingly, in particular embodiments, the present inven
tion encompasses truncated forms of the mature FGF21
polypeptide or FGF21 protein variants having both N-termi
nal truncations of 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues
and C-terminal truncations of 1,2,3,4,5,6,7,8,9, 10, 11, or
12 amino acid residues.

0201 As with all FGF21 variants of the present invention,
truncated FGF21 polypeptides can optionally comprise an
amino-terminal methionine residue, which can be introduced

by directed mutation or as a result of a bacterial expression
process.

0202 The truncated FGF21 polypeptides of the present
invention can be prepared as described in the examples
described herein. Those of ordinary skill in the art, familiar
with Standard molecular biology techniques, can employ that
knowledge, coupled with the instant disclosure, to make and
use the truncated FGF21 polypeptides of the present inven
tion. Standard techniques can be used for recombinant DNA,
oligonucleotide synthesis, tissue culture, and transformation
(e.g., electroporation, lipofection). See, e.g., Sambrook et al.,
Molecular Cloning: A Laboratory Manual, supra, which is
incorporated herein by reference for any purpose. Enzymatic
reactions and purification techniques can be performed
according to manufacturer's specifications, as commonly
accomplished in the art, or as described herein. Unless spe
cific definitions are provided, the nomenclatures utilized in
connection with, and the laboratory procedures and tech
niques of analytical chemistry, synthetic organic chemistry,
and medicinal and pharmaceutical chemistry described
herein are those well known and commonly used in the art.
Standard techniques can be used for chemical syntheses;
chemical analyses; pharmaceutical preparation, formulation,
and delivery; and treatment of patients.
0203 The truncated FGF21 polypeptides of the present
invention can also be fused to another entity, which can
impart additional properties to the truncated FGF21 polypep
tide. In one embodiment of the present invention, a truncated
FGF21 polypeptide can be fused to an IgG constant domain or
fragment thereof (e.g., the Fc region), Human Serum Albu
min (HSA), or albumin-binding polypeptides. Such fusion
can be accomplished using known molecular biological
methods and/or the guidance provided herein. The benefits of
Such fusion polypeptides, as well as methods for making Such
fusion polypeptides, are discussed in more detail herein.
FGF21 Fusion Proteins

0204 As used herein, the term “FGF21 fusion polypep
tide' or “FGF21 fusion protein’ refers to a fusion of one or
more amino acid residues (such as a heterologous protein or
peptide) at the N-terminus or C-terminus of any FGF21 pro
tein variant described herein.

0205 FGF21 fusion proteins can be made by fusing het
erologous sequences at either the N-terminus or at the C-ter
minus of, for example, an FGF21 protein variant, as defined

herein. As described herein, a heterologous sequence can be
anamino acid sequence or a non-amino acid-containing poly
mer. Heterologous sequences can be fused either directly to
the FGF21 protein variant or via a linker or adapter molecule.
A linker or adapter molecule can be one or more amino acid
residues (or-mers), e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 residues (or
-mers), preferably from 10 to 50 amino acid residues (or
-mers), e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30,
35, 40, 45, or 50 residues (or -mers), and more preferably
from 15 to 35 amino acid residues (or -mers). A linker or
adapter molecule can also be designed with a cleavage site for
a DNA restriction endonuclease or for a protease to allow for
the separation of the fused moieties.
0206 Heterologous peptides and polypeptides include,
but are not limited to, an epitope to allow for the detection
and/or isolation of an FGF21 protein variant; a transmem
brane receptor protein or a portion thereof. Such as an extra
cellular domain or a transmembrane and intracellular

domain; a ligand or a portion thereof which binds to a trans
membrane receptor protein; an enzyme or portion thereof
which is catalytically active; a polypeptide or peptide which
promotes oligomerization, such as a leucine Zipper domain; a
polypeptide or peptide which increases stability, Such as an
immunoglobulin constant region; a functional or non-func
tional antibody, or a heavy or light chain thereof, and a
polypeptide which has an activity, Such as a therapeutic activ
ity, different from the FGF21 protein variants of the present
invention. Also encompassed by the present invention are
FGF21 mutants fused to human serum albumin (HSA).
0207 a. Fc Fusions
0208. In one embodiment of the present invention, an
FGF21 protein variant is fused to one or more domains of an
Fc region of human IgG. Antibodies comprise two function
ally independent parts, a variable domain known as “Fab.”
that binds an antigen, and a constant domain known as "Fc.
that is involved in effector functions such as complement
activation and attack by phagocytic cells. An Fc has a long
serum half-life, whereas a Fab is short-lived (Capon et al.,
1989, Nature 337: 525-31). When joined together with a
therapeutic protein, an Fc domain can provide longer half-life
or incorporate Such functions as Fc receptor binding, protein
A binding, complement fixation, and perhaps even placental
transfer (Capon et al., 1989).
(0209 Throughout the disclosure, Fc-FGF21 refers to a
fusion protein in which the Fc sequence is fused to the N-ter
minus of FGF21. Similarly, throughout the disclosure,
FGF21-Fc refers to a fusion protein in which the Fc sequence
is fused to the C-terminus of FGF21.

0210 Preferred embodiments of the invention are
Fc-FGF21 fusion proteins comprising FGF21 variants as
defined herein. Particularly preferred embodiments are Fc
FGF21 fusion proteins comprising a modified Fc fragment
(e.g., an FcLALA) and FGF21 variants as defined herein.
0211 Fusion protein can be purified, for example, by the
use of a Protein A affinity column. Peptides and proteins fused
to an Fc region have been found to exhibit a substantially
greater half-life in vivo than the unfused counterpart. Also, a
fusion to an Fc region allows for dimerization/multimeriza
tion of the fusion polypeptide. The Fc region can be a natu
rally occurring Fc region, or can be altered to improve certain
qualities, such as therapeutic qualities, circulation time, or
reduced aggregation.
0212. Useful modifications of protein therapeutic agents
by fusion with the “Fc domain of an antibody are discussed
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in detail in PCT Publication No. WOOO/O24782. This docu

ment discusses linkage to a "vehicle'. Such as polyethylene
glycol (PEG), dextran, or an Fc region.
0213 b. Fusion Protein Linkers
0214. When forming the fusion proteins of the present
invention, a linker can, but need not, be employed. When
present, the linker's chemical structure may not critical, since
it serves primarily as a spacer. The linker can be made up of
amino acids linked together by peptide bonds. In some
embodiments of the present invention, the linker is made up
of from 1 to 20 amino acids linked by peptide bonds, wherein
the amino acids are selected from the 20 naturally occurring
amino acids. In various embodiments, the 1 to 20 amino acids

are selected from the amino acids glycine, serine, alanine,
proline, asparagine, glutamine, and lysine. In some embodi
ments, a linker is made up of a majority of amino acids that are
sterically unhindered, such as glycine and alanine. In some
embodiments, linkers are polyglycines, polyalanines, combi
nations of glycine and alanine (such as poly(Gly-Ala)), or
combinations of glycine and serine (such as poly(Gly-Ser)).
While a linker of 15 amino acid residues has been found to

work particularly well for FGF21 fusion proteins, the present
invention contemplates linkers of any length or composition.
0215. The linkers described herein are exemplary, and
linkers that are much longer and which include other residues
are contemplated by the present invention. Non-peptide link
ers are also contemplated by the present invention. For
example, alkyl linkers such as can be used. These alkyl linkers
can further be substituted by any non-sterically hindering
group, including, but not limited to, a lower alkyl (e.g.,
C1-C6), lower acyl, halogen (e.g., Cl, Br), CN. NH2, or
phenyl. An exemplary non-peptide linker is a polyethylene
glycol linker, wherein the linker has a molecular weight of
100 to 5000 kD, for example, 100 to 500 kD.
Chemically-Modified Fusion Proteins
0216 Chemically modified forms of the fusion proteins
described herein, including, e.g., truncated and variant forms
of the FGF21 fusions described herein, can be prepared by
one skilled in the art, given the disclosures described herein.
Such chemically modified Fusion Proteins are altered such
that the chemically modified mutant is different from the
unmodified mutant, either in the type or location of the mol
ecules naturally attached to the mutant. Chemically modified
mutants can include molecules formed by the deletion of one
or more naturally-attached chemical groups.
0217. In one embodiment, proteins of the present inven
tion can be modified by the covalent attachment of one or
more polymers. For example, the polymer selected is typi
cally water-soluble so that the protein to which it is attached
does not precipitate in an aqueous environment, such as a
physiological environment. Included within the scope of suit
able polymers is a mixture of polymers. Preferably, for thera
peutic use of the end-product preparation, the polymer will be
pharmaceutically acceptable. Non-water soluble polymers
conjugated to proteins of the present invention also form an
aspect of the invention.
0218 Exemplary polymers each can be of any molecular
weight and can be branched or unbranched. The polymers
each typically have an average molecular weight of between
about 2 kDa to about 100 kDa (the term “about indicating
that in preparations of a water-soluble polymer, Some mol
ecules will weigh more and some less than the Stated molecu
lar weight). The average molecular weight of each polymer is

Mar. 28, 2013

preferably between about 5 kDa and about 50 kDa, more
preferably between about 12 kDa and about 40kDa, and most
preferably between about 20 kDa and about 35 kDa.
0219 Suitable water-soluble polymers or mixtures thereof
include, but are not limited to, N-linked or O-linked carbo

hydrates, Sugars, phosphates, polyethylene glycol (PEG) (in
cluding the forms of PEG that have been used to derivatize
proteins, including mono-(C1-C10), alkoxy-, or aryloxy
polyethylene glycol), monomethoxy-polyethylene glycol,
dextran (Such as low molecular weight dextran of for
example, about 6 kD), cellulose, or other carbohydrate based
polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol,
propylene glycol homopolymers, polypropylene oxide/ethyl
ene oxide co-polymers, polyoxyethylated polyols (e.g., glyc
erol), and polyvinyl alcohol. Also encompassed by the
present invention are bifunctional crosslinking molecules
that can be used to prepare covalently attached FGF21 protein
variant multimers. Also encompassed by the present inven
tion are FGF21 mutants covalently attached to polysialic
acid.

0220 Polysaccharide polymers are another type of water
soluble polymer that can be used for protein modification.
Therefore, the fusion proteins of the invention fused to a
polysaccharide polymer form embodiments of the present
invention. Dextrans are polysaccharide polymers comprised
of individual subunits of glucose predominantly linked by
alpha 1-6 linkages. The dextran itself is available in many
molecular weight ranges, and is readily available in molecu
lar weights from about 1 kD to about 70 kD. Dextran is a
suitable water-soluble polymer for use as a vehicle by itselfor
in combination with another vehicle (e.g., Fc). See, e.g.,
International Publication No. WO96/11953. The use of dex

tran conjugated to therapeutic or diagnostic immunoglobu
lins has been reported. See, e.g., European Patent Publication
No. 0315 456, which is hereby incorporated by reference.
The present invention also encompasses the use of dextran of
about 1 kD to about 20 kD.

0221. In general, chemical modification can be performed
under any suitable condition used to react a protein with an
activated polymer molecule. Methods for preparing chemi
cally modified polypeptides will generally comprise the steps
of: (a) reacting the polypeptide with the activated polymer
molecule (such as a reactive ester or aldehyde derivative of
the polymer molecule) under conditions whereby a FGF21
protein variant becomes attached to one or more polymer
molecules, and (b) obtaining the reaction products. The opti
mal reaction conditions will be determined based on known

parameters and the desired result. For example, the larger the
ratio of polymer molecules to protein, the greater the percent
age of attached polymer molecule. In one embodiment of the
present invention, chemically modified FGF21 mutants can
have a single polymer molecule moiety at the amino-terminus
(see, e.g., U.S. Pat. No. 5,234,784)
0222. In another embodiment of the present invention,
Proteins of the invention can be chemically coupled to biotin.
The biotin/Proteins of the invention are then allowed to bind

to avidin, resulting in tetravalent avidin/biotin/Proteins of the
invention. Proteins of the invention can also be covalently
coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and
the resulting conjugates precipitated with anti-DNP or anti
TNP-IgM to form decameric conjugates with a valency of 10.
0223 Generally, conditions that can be alleviated or
modulated by the administration of the present chemically
modified FGF21 mutants include those described herein for
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Proteins of the invention. However, the chemically modified
FGF21 mutants disclosed herein can have additional activi

ties, enhanced or reduced biological activity, or other charac
teristics, such as increased or decreased half-life, as com

pared to unmodified FGF21 mutants.
Therapeutic Compositions of Fusion Proteins and
Administration Thereof

0224. The present invention also provides therapeutic
compositions comprising one or more of the fusion proteins
of the invention described herein and in admixture with a

pharmaceutically or physiologically acceptable formulation
agent orpharmaceutically acceptable carrier selected for Suit
ability with the mode of administration. The compositions are
specifically contemplated in light of, e.g., the identification of
fusions proteins exhibiting enhanced properties.
0225. In some embodiments the therapeutic compositions
are prepared as injectables, either as liquid Solutions or Sus
pensions; Solid forms suitable for solution in, or Suspension
in, liquid vehicles prior to injection can also be prepared.
Liposomes are included within the definition of a pharmaceu
tically acceptable carrier. Pharmaceutically acceptable salts
can also be present in the pharmaceutical composition, e.g.,
mineral acid salts such as hydrochlorides, hydrobromides,
phosphates, Sulfates, and the like; and the salts of organic
acids such as acetates, propionates, malonates, benzoates,
and the like. A thorough discussion of pharmaceutically
acceptable excipients is available in Remington: The Science
and Practice of Pharmacy (1995) Alfonso Gennaro, Lippin
cott, Williams, & Wilkins.

0226. Acceptable formulation materials preferably are
nontoxic to recipients at the dosages and concentrations
employed.
0227. The pharmaceutical composition can contain for
mulation materials for modifying, maintaining, or preserv
ing, for example, the pH, osmolarity, Viscosity, clarity, color,
isotonicity, odor, Sterility, stability, rate of dissolution or
release, adsorption, or penetration of the composition. Suit
able formulation materials include, but are not limited to,

amino acids (such as glycine, glutamine, asparagine, argin
ine, or lysine), antimicrobials, antioxidants (such as ascorbic
acid, Sodium sulfite, or sodium hydrogen-sulfite), buffers
(such as borate, bicarbonate, Tris-HCl, citrates, phosphates,
or other organic acids), bulking agents (such as mannitol or
glycine), chelating agents (such as ethylenediamine tetraace
tic acid (EDTA)), complexing agents (such as caffeine, poly
vinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta
cyclodextrin), fillers, monosaccharides, disaccharides, and
other carbohydrates (such as glucose, mannose, or dextrins),
proteins (such as serum albumin, gelatin, or immunoglobu
lins), coloring, flavoring and diluting agents, emulsifying
agents, hydrophilic polymers (such as polyvinylpyrrolidone),
low molecular weight polypeptides, salt-forming counterions
(such as sodium), preservatives (such as benzalkonium chlo
ride, benzoic acid, salicylic acid, thimerosal, phenethyl alco
hol, methylparaben, propylparaben, chlorhexidine, Sorbic
acid, or hydrogen peroxide), solvents (such as glycerin, pro
pylene glycol, or polyethylene glycol), Sugar alcohols (such
as mannitol or Sorbitol), Suspending agents, Surfactants or
wetting agents (such as pluronics; PEG, Sorbitan esters;
polysorbates such as polysorbate 20 or polysorbate 80; triton;
tromethamine; lecithin; cholesterol or tyloxapal), stability
enhancing agents (such as Sucrose or Sorbitol), tonicity
enhancing agents (such as alkali metal halides; preferably

Sodium or potassium chloride; or mannitol Sorbitol), delivery
vehicles, diluents, excipients and/or pharmaceutical adju
vants (see, e.g., Remington's Pharmaceutical Sciences (18th
Ed., A. R. Gennaro, ed., Mack Publishing Company 1990),
and Subsequent editions of the same, incorporated herein by
reference for any purpose).
0228. The optimal pharmaceutical composition will be
determined by a skilled artisan depending upon, for example,
the intended route of administration, delivery format, and
desired dosage (see, e.g., Remington’s Pharmaceutical Sci
ences, Supra). Such compositions can influence the physical
state, stability, rate of in vivo release, and rate of in vivo
clearance of the fusion protein of the invention.
0229. The primary vehicle or carrier in a pharmaceutical
composition can be either aqueous or non-aqueous in nature.
For example, a suitable vehicle or carrier for injection can be
water, physiological saline Solution, or artificial cerebrospi
nal fluid, possibly Supplemented with other materials com
mon in compositions for parenteral administration. Neutral
buffered saline or saline mixed with serum albumin are fur

ther exemplary vehicles. Other exemplary pharmaceutical
compositions comprise Tris buffer of about pH 7.0-8.5, or
acetate buffer of about pH 4.0–5.5, which can further include
sorbitol or a suitable substitute. In one embodiment of the

present invention, dual function pharmaceutical composi
tions can be prepared for storage by mixing the selected
composition having the desired degree of purity with optional
formulation agents (Remington's Pharmaceutical Sciences,
Supra) in the form of a lyophilized cake or an aqueous solu
tion. Further, the dual function protein product can be formu
lated as a lyophilizate using appropriate excipients such as
SUCOS.

0230. The pharmaceutical compositions containing the
fusion proteins of the invention can be selected for parenteral
delivery. Alternatively, the compositions can be selected for
inhalation or for delivery through the digestive tract, such as
orally. The preparation of Such pharmaceutically acceptable
compositions is within the skill of the art.
0231. The formulation components are present in concen
trations that are acceptable to the site of administration. For
example, buffers are used to maintain the composition at
physiological pH or at a slightly lower pH, typically within a
pH range of from about 5 to about 8.
0232. When parenteral administration is contemplated,
the therapeutic compositions for use in this invention can be
in the form of a pyrogen-free, parenterally acceptable, aque
ous Solution comprising the desired dual function protein in a
pharmaceutically acceptable vehicle. A particularly Suitable
vehicle for parenteral injection is sterile distilled water in
which a dual function protein is formulated as a sterile, iso
tonic Solution, properly preserved. Yet another preparation
can involve the formulation of the desired molecule with an

agent, such as injectable microspheres, bio-erodible particles,
polymeric compounds (such as polylactic acid or polygly
colic acid), beads, or liposomes, that provides for the con
trolled or sustained release of the product which can then be
delivered via a depot injection. Hyaluronic acid can also be
used, and this can have the effect of promoting Sustained
duration in the circulation. Other suitable means for the intro

duction of the desired molecule include implantable drug
delivery devices.
0233. In one embodiment, a pharmaceutical composition
can beformulated for inhalation. For example, a dual function
protein of the invention can beformulated as a dry powder for
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inhalation. Dual function protein inhalation Solutions can
also be formulated with a propellant for aerosol delivery. In
yet another embodiment, solutions can be nebulized. Pulmo
nary administration is further described in International Pub
lication No. WO 94/20069, which describes the pulmonary
delivery of chemically modified proteins.
0234. It is also contemplated that certain formulations can
be administered orally. In one embodiment of the present
invention, Fusion Proteins of the invention that are adminis
tered in this fashion can be formulated with or without those

carriers customarily used in the compounding of solid dosage
forms such as tablets and capsules. For example, a capsule
can be designed to release the active portion of the formula
tion at the point in the gastrointestinal tract when bioavail
ability is maximized and pre-systemic degradation is mini
mized. Additional agents can be included to facilitate
absorption of the fusion proteins of the invention. Diluents,
flavorings, low melting point waxes, vegetable oils, lubri
cants, Suspending agents, tablet disintegrating agents, and
binders can also be employed.
0235 Another pharmaceutical composition can involve an
effective quantity of the fusion proteins of the invention in a
mixture with non-toxic excipients that are suitable for the
manufacture of tablets. By dissolving the tablets in sterile
water, or another appropriate vehicle, solutions can be pre
pared in unit-dose form. Suitable excipients include, but are
not limited to, inert diluents, such as calcium carbonate,

Sodium carbonate or bicarbonate, lactose, or calcium phos
phate; or binding agents, such as starch, gelatin, or acacia; or
lubricating agents such as magnesium Stearate, Stearic acid,
or talc.

0236 Additional pharmaceutical compositions compris
ing Fusion Proteins of the invention will be evident to those
skilled in the art, including formulations involving Fusion
Proteins of the invention in sustained- or controlled-delivery
formulations. Techniques for formulating a variety of other
Sustained- or controlled-delivery means, such as liposome
carriers, bio-erodible microparticles or porous beads and
depot injections, are also known to those skilled in the art
(see, e.g., International Publication No.WO 93/15722, which
describes the controlled release of porous polymeric micro
particles for the delivery of pharmaceutical compositions,
and Wischke & Schwendeman, 2008, Int. J. Pharm. 364:

298-327, and Freiberg & Zhu, 2004, Int. J. Pharm. 282: 1-18,
which discuss microsphere/microparticle preparation and
use).
0237 Additional examples of sustained-release prepara
tions include semipermeable polymer matrices in the form of
shaped articles, e.g. films, or microcapsules. Sustained
release matrices can include polyesters, hydrogels, polylac
tides (U.S. Pat. No. 3,773.919 and European Patent No. 0.058
481), copolymers of L-glutamic acid and gamma ethyl-Lglutamate (Sidman et al., 1983, Biopolymers 22: 547-56),
poly(2-hydroxyethyl-methacrylate) (Langer et al., 1981, J.
Biomed. Mater. Res. 15: 167-277 and Langer, 1982, Chem.
Tech. 12: 98-105), ethylene vinyl acetate (Langer et al.,
supra) or poly-D-3-hydroxybutyric acid (European Patent
No. 0 133988). Sustained-release compositions can also
include liposomes, which can be prepared by any of several
methods known in the art. See, e.g., Epstein et al., 1985, Proc.
Natl. Acad. Sci. U.S.A. 82: 3688-92; and European Patent
Nos. 0.036 676, O 088 046, and 0 143 949.

0238. The pharmaceutical compositions of the invention
to be used for in vivo administration typically must be sterile.
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This can be accomplished by filtration through sterile filtra
tion membranes. Where the composition is lyophilized, ster
ilization using this method can be conducted either prior to, or
following, lyophilization and reconstitution. The composi
tion for parenteral administration can be stored in lyophilized
form or in a solution. In addition, parenteral compositions
generally are placed into a container having a sterile access
port, for example, an intravenous Solution bag or vial having
a stopper pierceable by a hypodermic injection needle.
0239. Once the pharmaceutical composition has been for
mulated, it can be stored in sterile vials as a solution, Suspen
Sion, gel, emulsion, Solid, or as a dehydrated or lyophilized
powder. Such formulations can be stored either in a ready-to
use form or in a form (e.g., lyophilized) requiring reconstitu
tion prior to administration.
0240. In a specific embodiment, the present invention is
directed to kits for producing a single-dose administration
unit. The kits can each contain both a first container having a
dried protein and a second container having an aqueous for
mulation. Also included within the scope of this invention are
kits containing single and multi-chambered pre-filled
Syringes (e.g., liquid Syringes and lyosyringes).
Dosages of Fusion Proteins and Administration Thereof
0241 The effective amount of an pharmaceutical compo
sition of the invention to be employed therapeutically will
depend, for example, upon the therapeutic context and objec
tives. One skilled in the art will appreciate that the appropriate
dosage levels for treatment will thus vary depending, in part,
upon the molecule delivered, the indication for which the
fusion protein variant is being used, the route of administra
tion, and the size (body weight, body Surface, or organ size)
and condition (the age and general health) of the patient.
Accordingly, the clinician cantiter the dosage and modify the
route of administration to obtain the optimal therapeutic
effect. A typical dosage can range from about 0.1 ug/kg to up
to about 100 mg/kg or more, depending on the factors men
tioned above. In other embodiments, the dosage can range
from 0.1 ug/kg up to about 100 mg/kg, or 1 ug/kg up to about
100 mg/kg.
0242. The frequency of dosing will depend upon the phar
macokinetic parameters of the dual function protein in the
formulation being used. Typically, a clinician will administer
the composition until a dosage is reached that achieves the
desired effect. The composition can therefore be adminis
tered as a single dose, as two or more doses (which may or
may not contain the same amount of the desired molecule)
over time, or as a continuous infusion via an implantation
device or catheter. Further refinement of the appropriate dos
age is routinely made by those of ordinary skill in the art and
is within the ambit of tasks routinely performed by them.
Appropriate dosages can be ascertained through use of appro
priate dose-response data.
0243 The route of administration of the pharmaceutical
composition is in accord with known methods, e.g., orally;
through injection by intravenous, intraperitoneal, intracere
bral (intraparenchymal), intracerebroventricular, intramus
cular, intraarterial, intraportal, or intralesional routes; by Sus
tained release systems (which may also be injected); or by
implantation devices. Where desired, the compositions can be
administered by bolus injection or continuously by infusion,
or by implantation device.
0244 Alternatively or additionally, the composition can
be administered locally via implantation of a membrane,
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sponge, or other appropriate material onto which the desired
molecule has been absorbed or encapsulated. Where an
implantation device is used, the device can be implanted into
any suitable tissue or organ, and delivery of the desired mol

Publications); and Sambrook et al., Molecular Cloning: A
Laboratory Manual (2nd Edition, 1989).
EXAMPLES

ecule can be via diffusion, timed-release bolus, or continuous

Example 1

administration.

Therapeutic Uses of Fusion Proteins
0245 Proteins of the invention can be used to treat, diag
nose, ameliorate, or prevent a number of diseases, disorders,
or conditions, including, but not limited to metabolic disor
ders. In one embodiment, the metabolic disorder to be treated

is diabetes, e.g., type 2 diabetes mellitus. In another embodi
ment, the metabolic disorder is obesity. Other embodiments
include metabolic conditions or disorders such as type 1
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic
fatty liver disease (NAFLD), nonalcoholic steatohepatitis
(NASH), insulin resistance, hyperinsulinemia, glucose intol
erance, hyperglycemia, metabolic syndrome, hypertension,
cardiovascular disease, acute myocardial infarction, athero
Sclerosis, peripheral arterial disease, stroke, heart failure,
coronary heart disease, kidney disease, diabetic complica
tions, neuropathy, disorders associated with severe inactivat
ing mutations in the insulin receptor, gastroparesis and other
metabolic disorders.

0246. In application, a disorder or condition Such as type 1
or type 2 diabetes mellitus or obesity can be treated by admin
istering an FGF21 protein variant as described herein to a
patient in need thereof in the amount of a therapeutically
effective dose. The administration can be performed as
described herein, such as by IV injection, intraperitoneal
injection, intramuscular injection, or orally in the form of a
tablet or liquid formation. In most situations, a desired dosage
can be determined by a clinician, as described herein, and can
represent a therapeutically effective dose of the FGF21
mutant polypeptide. It will be apparent to those of skill in the
art that a therapeutically effective dose of FGF21 mutant
polypeptide will depend, inter alia, upon the administration
schedule, the unit dose of antigen administered, whether the
nucleic acid molecule or polypeptide is administered in com
bination with other therapeutic agents, the immune status and
the health of the recipient. The term “therapeutically effective

Preparation of FGF21 Variant Proteins
0249 Expression Construct for FGF21 V76:
(0250. The FGF21 variants were cloned into the modified
E. coli expression vector pET30a, described by Achmuller et
al. (2007) (Nature Methods 4:1037-1043), to generate in
frame fusions to a hexa-histidine tag followed by the N'EDDIE tag at the N-terminus of FGF21 (aa 33-209).
(0251 Expression and Purification of FGF21 V76:
0252. The pET30a-His-N-EDDIE-FGF21 expression
plasmid was transformed into E. coli BL21 Star (DE3) com
petent cells (Invitrogen). Overnight growth from a single
colony of freshly transformed cells was carried out in 50 mL
of Terrific Broth (TB) containing 50 ug/mL of kanamycin at
37°C. The pre-culture was transferred into 1 L of TB medium
with kanamycin and cultured in baffled flasks at 37°C. with
shaking at 250 rpm. After 6 hour of culture, expression of
FGF21 was induced by the addition of IPTG at a final con
centration of 1 mM, and the cultures were grown overnight at
37°C. The cells were then harvested and resuspended into 50
mL of ice-cold lysis buffer; 50 mM Tris-HCl, pH 8, 150 mM
NaCl, 1 mM EDTA, followed by lysis using a Microfluid
ZerTM.

0253 Inclusion bodies (IBs) were precipitated by cen
trifugation at 30,000xg for 1 hour at 4°C. The IBs were
washed with 50 mM Tris-HCl, pH 8, 150 mM. NaCl and then
dissolved into 30 mL of dissolving buffer; 10 mM Tris-HCl,
pH8, 100mMNaHPO, 6 MGnHC1. The dissolved IBs were
clarified by centrifugation at 30,000xg for 1 hour at 25°C.
The IB solution was loaded onto a 5 mL column of Ni-NTA

unless otherwise indicated, conventional methods of chemis

high performance resin (GE Healthcare) equilibrated with the
dissolving buffer. Proteins bound to the resin were eluted by
decreasing the pH to 4.5. The eluate was conditioned by
adjusting pH and adding dithiothreitol (DTT) at a concentra
tion of 20 mM. The conditioned eluate was slowly diluted into
1 L of refolding buffer; 50 mM Tris-HCl, pH 8, 0.5 Margin
ine, 20 mM DTT, followed by incubation for 2 days at 4°C.
The diluted sample was concentrated and buffer-exchanged
into 20 mM Tris-HCl, pH 9 using an ultrafiltration method.
The concentrated sample was loaded onto a 10 mL column of
Qsepharose fast flow resin (GE Healthcare) equilibrated with
20 mM Tri-HCl (pH9).
0254. After washing the resin with the equilibration
buffer, proteins bound to the resin were eluted with 20 mM
Tris-HCl, pH 9, 500 mM. NaCl. To remove the cleaved off
His-N' fusion fragment and any uncleaved fusion protein
from the refolded FGF21 protein, the eluate was loaded onto
a 5 mL column of Ni-NTA high performance resin equili
brated with 20 mM Tris, pH 8.0, 50 mM imidazole, and the
flow-through fraction containing FGF21 was collected. To

Weir and C. C. Blackwell, eds., 1986, Blackwell Scientific

an EndoTrap HD resin (Hyglos) equilibrated with 10 mM
Tris, pH 8,50 mM imidazole, 500 mM. NaCl, 1 mM CaCl.
The low-endotoxin sample was dialyzed against PBS and
then sterilized with a 0.22 um filter. The purified FGF21
protein was Snap-frozen in liquid nitrogen and stored at -80°
C. Protein concentration was determined by absorbance at
280 nm using 93.62 M-1 cm-1 as the molar extinction coeffi

dose” as used herein, means that amount of FGF21 mutant

polypeptide that elicits the biological or medicinal response
in a tissue system, animal, or human being sought by a
researcher, medical doctor, or other clinician, which includes

alleviation of the symptoms of the disease or disorder being
treated.

0247 Having now described the present invention in
detail, the same will be more clearly understood by reference
to the following examples, which are included herewith for
purposes of illustration only and are not intended to be lim
iting of the invention.
0248. The practice of the present invention will employ,
try, biochemistry, molecular biology, immunology and phar
macology, within the skill of the art. Such techniques are
explained fully in the literature. See, e.g., Remington's Phar
maceutical Sciences, 18th Edition (Easton, Pa.; Mack Pub
lishing Company, 1990); Methods In Enzymology (S. Colow
ick and N. Kaplan, eds., Academic Press, Inc.); and
Handbook of Experimental Immunology, Vols. I-IV (D. M.

reduce endotoxin levels, the FGF21 fraction was treated with
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cient for FGF21. Protein purity and integrity were determined
by HPLC, SDS-PAGE and liquid chromatography-mass
spectrometry.

0255 Cysteine PEGylation of FGF21 Variants:
0256 FGF21 Variant V76 (R154C) variant has the ten
dency to dimerize via the engineered cysteine; therefore,
prior to PEGylation the protein solution (typically 5 mg/mL
in Tris buffer) was mildly reduced with 5 mM mercaptoethy
lamine for 30 minutes on ice and immediately desalted in 20
mM Tris, pH 7. The freshly reduced protein (typically 3
mg/mL) was then immediately PEGylated with 1.5 equiva
lent of 40 kDa branched maleimido-PEG reagent (NOF, Cat.
#GL2-400MA from the Sunbright series) for 3 hours on ice.
The PEGylated protein was finally purified by anion
exchange chromatography (MonoC) with overall yields of
about 25%.

0257 Expression Constructs for Fc-FGF21 Fusion Vari
antS:

0258. The cDNAs for human FGF21 variants encoding
amino acids 33-209 were cloned into a mammalian expres
sion vector downstream of the cytomegalovirus (CMV) pro
moter in-frame with N-terminal sequences including a leader
peptide (immunoglobulin kappa-chain) to direct secretion of
the proteins, followed by an Fc domain and a short linker.
0259 Expression and Purification of Fc-FGF21 Variants:
0260 The Fc-FGF21 variant proteins were expressed into
HEK293T cells (American Type Culture Collection). Cells
were grown in suspension culture at 37° C., 8% CO, in
Freestyle 293 Expression Medium (Invitrogen, Cat. #12338
018) until day of transfection. Cells were centrifuged at
1000xg for 7 min in a swinging bucket rotor and counted
using an automated cell counter. Cells were diluted in 900 mL

of Freestyle 293 media to a final concentration of 1.4x10'

cells/mL and placed into a 3 L non-baffled flask (Corning,
Cat. #431252). Cells were transfected using a mixture of
polyethyleneimine (PEI) and plasmid as follows. Three mL
of a sterile 1 mg/mL stock of linear, M.W. 25,000, PEI (Alfa
Aesar, Cat. #43896) was added to 50 mL of Freestyle 293
media, mixed gently and incubated at 25°C. for 5 minutes. At
the same time, 1 mg of endotoxin-free plasmid was added to
50 mL Freestyle 293 media and sterile filtered using a 0.22
uM filter. The PEI mixture was then added to the sterile

filtered DNA, mixed gently and allowed to incubate at 25°C.
for 10 minutes. The PEI-plasmid mixture was then added to
the 3 L flask containing the diluted HEK 293T cells and
placed at in a shaking incubator at 125 RPM, 37°C., 8% CO.
0261) On day 6 post-transfection, the cells were centri
fuged at 2000xg for 10 minutes and the supernatant was
harvested. The supernatant was further clarified by filtration
through a 0.8/0.2 uM filter (Pall Corporation, Cat. #4628).
0262 Batch purification of the FGF21 protein was done
by adding 1 mL of recombinant Protein A Sepharose Fast
Flow (GE, Cat. #17-5138-03), per 20 mg of expected protein
to be purified, directly to the clarified supernatant and incu
bating for 1 hour at 4°C. with gentle rotation. The supernatant
mixture was then poured over a disposable Poly-Prep Chro
matography Column (Bio-Rad, Cat. #731-1550) and the flow
through was discarded. The retained beads were washed with
5 column volumes of DPBS, pH7.4 (Invitrogen, Cat. #14190
144). Elution of the protein from the Protein A beads was
done by adding 20 column volumes of 50 mMSodium Citrate
buffer, pH 3.0. The elution buffer was neutralized by the
addition of 20% Tris-HCL buffer, pH 9.0. Size exclusion
chromatography was preformed as a secondary polishing step

Mar. 28, 2013

by running the Protein Abatch purified material over a High
Load 26/600 Superdex 200 pg column (GE, Cat. #28-9893
36). The purified protein yield was quantified by A280. SDS
Page was run to Verify purity and molecular weight. Endot
oxin level was quantified by using the Endosafe PTS system
(Charles River Labs).
Example 2
Measuring FGF21 Dependent 2-Deoxyglucose
(2-DOG) Uptake
0263 FGF21 has been shown to stimulate glucose-uptake
in mouse 3T3-L1 adipocytes in the presence and absence of
insulin, and to decrease fed and fasting blood glucose, trig
lycerides, and glucagon levels in ob/ob and db/db mice and 8
week old ZDF rats in a dose-dependent manner, thus, provid
ing the basis for the use of FGF21 as a therapy for treating
diabetes and obesity (see, e.g., patent publication WO03/
011213, and Kharitonenkov et al., (2005) Jour. of Clinical
Invest. 115:1627-1635). Also, FGF21 was observed to stimu
late tyrosine phosphorylation of FGFR-1 and FGFR-2 in
3T3-L1 adipocytes.
0264. T3-L1 fibroblasts were purchased from ATCC (Cat.
#CL173). The cells were grown to confluency in 150 cm
petri-dish and were maintained in DMEM with high glucose
(Invitrogen, Cat. #11995065) supplemented with 10% Fetal
Bovine Serum and 1% penicillin-streptomycin for an addi
tional 4 days. Cells were then differentiated in the above
media Supplemented with 4 g/mL insulin (Sigma, Cat.
#1-5500), 115 g/mL IBMX (Sigma, Cat. #15879) and
0.0975 ug/mL dexamethasone (Sigma, Cat. HD 1756) for 3
days after which the differentiation media was replaced with
complete DMEM. One plate of differentiated 3T3-L1 adipo
cytes were seeded into four 96-well plates the day after
medium replacement.
0265. The adipocytes were then treated with FGF21-WT
and FGF21 variant protein (see Table 2 for list of variants; 30
pM to 100 nM is the typical concentration range used) over
night in complete medium. The adipocytes treated with
FGF21 samples were serum starved in 50 uL per well KRH
buffer (0.75% NaCl; 0.038%. KCl; 0.0196% CaC1; 0.032%
MgSO, 0.025M HEPES, pH 7.5; 0.5% BSA; 2 mM sodium
pyruvate) for 2 hours. The wells for blank were added with 1
LL (final concentration 5 Jug/ml) cytochalasin B for 15 min.
[3H]-2-DOG (20.6 mCi/mmoL, 1 mCi/mL) was diluted 1:20
in 5.1 mM cold 2-DOG and 1 uL diluted 2-DOG was added
per well and the cells were incubated for 5 min. The cells were
washed with 100 uL/well KRH buffer three times. 40 uL/well
1% SDS was added to cells and the cells were shaken for at

least 10 minutes. 200 u/well scintillation fluid was added
and the plates were shaken overnight and read in beta-micro
plate reader. The values obtained from an entire column/row,
which were treated with cytochalasin B, was averaged and
subtracted from all other values. The data were analyzed by
GraphPad Prism software, the results of which are summa
rized in Table 2. Fc-FGF21 Fusion Variants V101, V103 and

V188 are superior to PEGylated FGF21 Variant V76 in for
induction of 2-deoxyglucose uptake by mouse 3T3L1 adipo
cytes.

Example 3
pERK In Cell Western (ICW) Assay
0266 HEK293 cells stably transfected with human
B-klotho were cultured in DMEM high glucose, 10% FBS,
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1% PS and 600 ng/mL G418 are seeded in poly-D-lysine
coated 96-well plates (BD bioscience, Cat. #356640) at
30,000 cells per well overnight. The cells were serum starved
in DMEM high glucose, 0.5% BSA and 10 mM HEPES for 4
hours. WTFGF21 and the FGF21 variants (see Table 3 for list
of variants) were diluted to various concentrations (100 pM to
300 nM is the typical concentration range used) in starvation

TABLE 2-continued
Summary of ERK in cell Western and Mouse 3T3L1
Adipocyte Glucose Uptake ASSay Results
pERK
(HEK293/human B-klotho)

FGF21
Variant ID

ECSO

Glucose Uptake
(Mouse 3T3-L1 adipocytes)

SEM

ECSO

SEM

medium. The cells were stimulated with FGF21 for 10 min

utes. Following FGF21 or FGF21 Variant protein stimulation,
the media was aspirated from the wells and the cells were
washed once with 100 uL cold PBS and then fixed with 100 ul
of 4% formaldehyde for 15 minutes at room temperature and
followed by an additional 10 minute incubation with 100 uL

V103
W188

0.9 + 0.3 nM (n = 5)
0.4 + 0.1 nM (n = 3)

0.60 + 0.07 nM (n = 3)
0.48 + 0.14 nM (n = 3)

Example 4

ice-cold methanol.

0267. After fixation, the cells were washed with 0.3%
Triton X-100 in PBS four times, 5 minutes each. 150 uL
Odyssey Blocking Buffer was added to the permeabilized
cells at room temperature for 1.5 hours. Phospho-ERK
(pERK) antibody was diluted to a concentration of 0.17
ug/mL (1:200 dilution, or the dilutions indicated), and total
ERK (tRK) antibody was diluted to a concentration of 2.2
ug/mL (1:200 dilution, or the dilutions indicated) in Odyssey
Blocking Buffer. 50LL was added to every well, omitting one
column which was only treated with secondary antibody to
normalize for background. The plate was covered with the
wet paper tower and lid to prevent evaporation and then
incubated at 4°C. overnight.
0268. Afterwards, the primary antibody was aspirated and
the cells were washed four times with 0.3% Tween 20 in PBS

for 5 minutes each. During the washing, the secondary anti
body reaction mixture was prepared in Odyssey Blocking
Buffer containing 1:1000-diluted (or the dilutions indicated)
goat anti-mouse Alexa 680 and 1:1000-diluted (or the dilu
tions indicated) IRDye800 goat anti-rabbit antibody. Once
the washing was completed, 40 uL of the reaction mixture
was added to each well. Plates were covered with black lid to
protect the secondary antibody from light, and plates were
incubated at room temperature for 1 hour on a shaker. Finally,
the cells were washed again four times with 0.3% Tween 20 in
PBS for 5 minutes each and then scanned on the LI-COR
Bioscience Odyssey Infrared Imaging System (Li-Cor Bio
sciences, Lincoln, Nebr.) in the 700 nm (red) and 800 nm
(green) channels. Alexa 680 stained the tERK with far-red
fluorescence (emission wavelength 668 nm), while
IRDye800 stained the pERK with green fluorescence (emis
sion wavelength 800 nm). To eliminate the fluorescent back
ground, the values obtained from an entire column/row,
which was treated with only secondary antibody, was aver
aged and subtracted from all other values obtained from the
plate. For normalization of the amount of pH.RK present in
each sample, the values for pERK in each well was divided by
the values of tERK. The data were analyzed by GraphPad
Prism software, the results of which are summarized in Table

In Vivo Tests of FGF21 Variants

0269. The ob?ob mouse is a mouse model for type 2 dia
betes. The mice lack functional leptin and are characterized
by hyperglycemia, insulin resistance, hyerphagia, hepatic Ste
atosis and obesity. Male ob?ob mice (10-13 weeks old) were
used to measure the effect on blood glucose of the following
PEGylated FGF21 variant V76 and Fc-FGF21 fusion variants
V101, V103 and V188.
0270 FGF21 variants or PBS vehicle were administered

s.c. at 1 mg/kg (V101, V103 and V188) or s.c at 5 mg/kg V76
twice per week 12 days (4 doses total). On the first day of the
study, tail blood glucose and body weight were measured and
mice were allocated into different groups (n=8 per group)
with mean glucose and body weight matched among the
groups. Blood glucose was measured using a glucometer
(OneTouch). Plasma insulin was measured on day 1 before
dosing and on day 12, 24 hours post the last dose. The results
of these studies are summarized in Table 5.

0271 The results of these studies are summarized in Table
3 and FIGS. 1-3. Fc-FGF21 Fusion Variants V101, V103 and

V188 are superior to PEGylated FGF21 Variant V76 on every
endpoint measured in these studies and at a five-fold lower
dose.
TABLE 3

% changes versus vehicle in plasma glucose, insulin,
body weight (BW) gain, liver TG/lipid by FGF21
variants during 12-day studies in objob mice.
Summary of 12-day treatment study in diabetic ob?ob mice
% change from vehicle
FGF21

Variant ID
V76
V101
V103
W188

Dose

Total
Glucose

Plasma

Body

(mg/kg)

(AUC)

Insulin

Weight

lipid

S.O
1.O
1.O
1.O

-42%
-53%
-46%
-42%

-46%
-82%
-69%
-59%

-7%
-1.2%
-1.2%
-1.1%

-30%
-44%
-50%
-51%

Liver

2. Fc-FGF21 Fusion Variants V101, V103 and V188 are supe
rior to PEGylated FGF21 Variant V76 in this ERK phospho
rylation assay.

Example 5

TABLE 2

Pharmacokinetics of FGF21 Fusion Variants in Mice

Summary of ERK in cell Western and Mouse 3T3L1
Adipocyte Glucose Uptake ASSay Results
FGF21
Variant ID

V76
V101

pERK
(HEK293/human B-klotho)
ECSO

SEM

13 + 4 nM (n = 5)
0.60 + 0.06 nM (n = 5)

Glucose Uptake
(Mouse 3T3L1 adipocytes)
ECSO

SEM

5 + 1 nM (n = 3)
0.60 + 0.06 nM (n = 3)

0272. To determine the pharmacokinetic profile of Fc
FGF21 Fusion Variants V101, V103 and V188, C57BL/6J

mice were injected IV with 1 mg/kg test article and bled at
various time points out to 16 days (384 hours). Blood samples
were collected into EDTA-coated microtainer tubes from

either the submandibular or retro-orbital plexus. Approxi
mately 50 uL of blood was collected at each time point,
yielding ~25 uL of plasma.
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0273 To measure plasma concentrations of testarticles by
ELISA, 384-well plates were coated overnight at room tem
perature (RD with 2 g/mL of anti-Human Fc-gamma goat
polyclonal antibody (30 uL/well) and then blocked with a
casein-based diluent for 2 hour at RT (100 uL/well). Diluted
samples, standards, and controls were added to the plate (30
uL/well) and incubated for 2 hour at RT. After the samples
were removed, the wells were washed 3 times with a phos
phate-based wash solution (100LL?well). The detection anti
body, an HRP-labeled version of the capture antibody, was
added to the plate and incubated for 1 hour at RT (30LL?well).
After the plate was again washed 3 times with a phosphate
based wash solution (100 uL/well), a chemiluminescent sub
strate was added (30 uI/well) and the plate luminescence was
read within 5 minutes using an appropriate plate reader. As
shown in FIGS. 4A and 4B the Fc-FGF21 fusion variants had

a greatly extended plasma half-life relative to known Fc
FGF21 fusions in the art (FIG. 4A) and relative to PEGylated
FGF21 variant V76 (FIG. 4B).
0274 Serum levels of Fc-FGF21 test articles were vali
dated by Western blot for comparison to levels measured by
ELISA to ensure that full length Fc-FGF21 variant and not Fc
alone was being detected in the ELISA. Two ul of mouse
serum was combined with 2.5uL of 4x loading buffer, 1 uL of
10x denaturant and 4 uL of dHO, heated to 95°C. for 5
minutes and loaded onto a 4-12% gradient polyacrylamide
gel and electrophoresed for 1 hour at 100 Volts (constant
voltage). Samples were transferred to nitrocellulose filter
paper by Western blot using the iblot system (Invitrogen, Cat.
#IB1001, 7 minute run time). The nitrocellulose filters were
blocked with 30 mL of Rockland blocking solution (Cat.
#MB-070), probed following the snap iblot system protocol
with a goat anti-FGF21 primary antibody at a 1:2000 dilution
(R&D systems, Cat. iBAF2539) and fluorescently labeled
streptavidin as a secondary at a 1:10000 dilution (Licor, Cat.
#926-68031). Protein levels were imaged on the Licor Odys

sey system at 700 nm and compared with 2 nM control V101
run on the same gel. As shown in FIG. 4C full-length Fc
FGF21 variants V101, V103 and V188 are detectable using on
a Western Blot using anti-FGF21 antibody out to 15 days
from mouse serum from the pharmacokinetic study.
Example 6
Fc-FGF21 Fusion Variants V101, V103 and V188 are

Extremely Thermodynamically Stabile
0275 Proteins can be unfolded at specific temperature
range. The temperature of protein unfolding is an intrinsic
parameter to describe thermal stability of proteins. Differen
tial Scanning calorimetry (DSC) is used to detect the unfold
ing temperature of protein. This characteristic temperature is
described as melting temperature (Tm), which is the peak
temperature during protein unfolding.
0276 Original protein samples are diluted in PBS to a
concentration of ~ 1 mg/ml (0.5 mg/ml to 1.2 mg/ml) for a
total volume of 0.5 ml. An aliquot of 0.4 ml per well diluted
protein sample, standard, PBS, and DI water are added to
DSC 96-well plate. The plate is then covered by a seal.
Samples were analyzed in a 96 well Differential Scanning
calorimeter from MicroCal. The temperature was scanned
from 10-110 degrees C. at a rate of 1 degree per minute.
0277 As shown in FIG. 4D the melting temperatures of
FGF21 variants V101, V103 and V188 are extremely high.
This is in contrast to the lower melting temperatures of
FGF21 variant V76 and wild-type FGF21 (not shown). We
attribute the improved stability of V101, V103 and V188 to
the specific addition of a second disulfide bond from the novel
Q55C and G148C mutations. This type of thermodynamic
stability is known to protect proteins from proteolysis and can
in addition translate into significantly prolonged Stability in
vivo and the improved pharmacokinetic profiles exemplified
by the data in FIGS. 4B and 4C.

SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS : 13
SEO ID NO 1
LENGTH: 209
TYPE PRT

ORGANISM: Homo sapiens
<4 OOs SEQUENCE: 1

Met Asp Ser Asp Glu Thir Gly Phe Glu His
1.

Ser

Gly

Wall Lieu. Ala

Trp Wall

Gly

Asp Ser

Luell Luell Luell

Gly

Ala

Cys Glin Ala His

25

Ser Pro Luell Luell Glin Phe
35
4O

Gly Gly

Glin Wall

SO

55

70

Ala Luell

7s
Pro

Gly

85

Thir Ser

Arg Phe

Luell

Arg Glin Arg
Luell Glu Ile

Arg

60

Asp Gly Thir Wall Gly Gly Ala Ala Asp Glin

Lieu. Glin Lell

Pro Ile Pro
3O

45

Leu Tyr Thir Asp Asp Ala Glin Glin Thir Glu Ala His

65

Ser

15

2O

Glu

Luell

5

Glin

Arg

Ser Pro Glu Ser Lell
8O

Wall Ile Glin Ile Tell

Gly

90

95

Pro

Asp Gly Ala

Tell

Wall

Gly
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1OO

105

11 O

Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu.
115

12 O

125

Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu.
13 O

135

14 O

His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Pro Arg Gly
145

150

155

160

Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu
1.65

17O

17s

Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp
18O

185

19 O

Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala
195

2OO

2O5

Ser

<210s, SEQ ID NO 2
&211s LENGTH: 940
&212s. TYPE: DNA

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 2

Ctgtcagctg aggatc.ca.gc cgaaagagga gcc aggcact caggccacct gag to tactic

6O

acctggacaa citggaatctg gcaccaattic taalaccactic agcttct cog agct cacacc

12 O

ccggagat.ca cctgaggacc cago cattg atggact cqg acgaga.ccgg gttcgagcac

18O

t caggactgt gggitttctgt gctggctggt Cttctgctgg gag cctgcca ggcacaccc.c

24 O

atcCctgact C cagtic ct ct cctgcaattic gggggccaag ticcggcagcg gtacctic tac

3OO

acagatgatg cccagcagac agaag.cccac ctggagat.ca gggaggatgg gacggtgggg

360

ggcgctgctg accagagc cc caaagttctic Ctgcagctga aagccttgaa gCCgggagtt

42O

attcaaatct tdgagt caa gaCat CCagg ttcctgtgcc agcggccaga tigggg.ccctg

48O

tatggat.cgc. tcc actittga C cctgaggcc ticagottcc gggagctgct tcttgaggac

54 O

ggatacaatgtttaccagtic Caag.cccac ggcct cocgc tigcacct gcc agggaacaag

6OO

tcc.ccacacc gggaccCtgc accc.cgagga C cagct cqct tcc ticcact accaggcctg

660

CCCC cc.gcac toccggagcc acccggaatc Ctggc.ccc.cc agc.ccc.ccga tigtgggct cc

72 O

tcggaccctic taggatggt gggacct tcc Cagggcc.gala gcc cc agct a cqctt CCtga

78O

agccagaggc tigtttact at gacat citcct ctittattitat taggittattt atc.ttattta

84 O

tttittt tatt tttct tactt gagataataa agagttccag aggagaaaaa aaaaaaaaaa

9 OO

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa.

94 O

<210s, SEQ ID NO 3
&211s LENGTH: 181
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 3

His Pro Ile Pro Asp Ser Ser Pro Leu Lieu. Glin Phe Gly Gly Glin Val
1.

5

1O

15

Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His
2O

25

3O

Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser
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35

4O

45

Pro Glu Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin
SO

55

6O

Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly
65

70

7s

8O

Ala Lieu. Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg
85

90

95

Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His
1OO

105

11 O

Gly Lieu Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro
115

12 O

125

Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Lieu Pro Pro
13 O

135

14 O

Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val
145

150

155

160

Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser
1.65

17O

17s

Pro Ser Tyr Ala Ser
18O

<210s, SEQ ID NO 4
&211s LENGTH: 546
&212s. TYPE: DNA

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 4

Caccc.cat co Ctgacticcag ticct Ctcct

caatt.cgggg gccaagt ccg gcagcgg tac

6O

Ctct acacag atgatgcc.ca gcagacagaa goccacctgg agat Caggga ggatgggacg

12 O

gtgggggg.cg Ctgctgacca gagcc.ccgala agt ct cotgc agctgaaagc Cttgaag.ccg

18O

ggagittatt c aaatcttggg agt caagaca toc aggttcc titgc.ca.gcg gcc agatggg

24 O

gccCtgtatg gat.cgcticca Ctttgaccct gaggcctgca gct tccggga gctgctt Ctt

3OO

gaggacggat acaatgttta C cagt ccgala gcc cacggcc ticcc.gctgca CctgcCaggg

360

aacaagtic cc cacaccggga ccctgcaccc cdaggaccag citcqct tcct gcc actacca

42O

ggcctgcc cc cc.gcactic cc ggagccaccc ggaatcc tig C cc cc cagcc ccc.cgatgtg

48O

ggct cotcgg accctctgag catggtggga cct tccCagg gcc.gaag.ccc cagctacgct

54 O

t cct ga

546

<210s, SEQ ID NO 5
&211s LENGTH: 28
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 5

Met Asp Ser Asp Glu Thr Gly Phe Glu. His Ser Gly Lieu. Trp Val Ser
1.

5

1O

Val Lieu Ala Gly Lieu. Lieu. Lieu. Gly Ala Cys Glin Ala
2O

<210s, SEQ ID NO 6
&211s LENGTH: 15
&212s. TYPE: DNA

<213> ORGANISM: Homo sapiens

25

15
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<4 OOs, SEQUENCE: 6
ggggsggggs ggggs

15

<210s, SEQ ID NO 7
&211s LENGTH: 406
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OO > SEQUENCE: 7

Asp Llys Thr His Thr Cys Pro
1.

Pro Ala Pro Glu Ala Ala
15

Pro

5

Gly Pro Ser Val Phe Leu Phe

Gly

Pro

Pro

Asp Thir

Luell Met

Thir

Wall Wall Wall

Asp Wall

Ser His

2O

Ile Ser Arg Thr Pro Glu Val
35

4O

Glu Asp Pro Glu Val Llys Phe
SO

Asn

45

Trp Tyr Wall Asp Gly Wall Glu Wall

55

6O

His Asn Ala Lys Thr Llys Pro Arg
65

Glu Glu Glin

Tyr

Asn Ser Thir

Tyr

70

Arg Val Val Ser Val Lieu. Thr

Wall Luell His Glin

85

Asp Trp

90

Lys Glu Tyr Lys Cys Llys Val
1OO

115

11 O

Glin Pro

Arg

12 O

Tyr Thr Lieu Pro Pro Ser Arg
13 O

145

Glu Glu Met Thir

Lys

Asn Glin Wall Ser

14 O

Phe

150

Trp. Glu Ser Asn Gly Glin Pro

Glu Pro Glin Wall
125

135

Lieu. Thir Cys Lieu Val Lys Gly

Gly

Ala Lell Pro Ala Pro Ile

Ser Asn
105

Glu Lys Thr Ile Ser Lys Ala Lys Gly

Luell Asn
95

Pro Ser
155

Asp Ile Ala Wall Glu

Tyr

Thir Thir Pro Pro

Glu Asn Asn

1.65

160

17O

Val Lieu. Asp Ser Asp Gly Ser

Phe Phe Luell

18O

185

Asp Llys Ser Arg Trp Glin Glin Gly

17s

Tyr

Luell Thir Wall
19 O

Ser

Asn Wall Phe Ser

Cys

Ser Wall Met

195

His Glu Ala Lieu. His Asn His
21 O

Thir Glin

Lys

215

Pro Gly Lys Gly Ser Asp Ser
225

23 O

Val Arg Glin Arg Tyr Lieu. Tyr

Ser Lell Ser Luell Ser
22O

Ser Pro Luell Luell Glin Phe
235

Thir

26 O

Thir Wall

255

Gly Gly

Ala Ala

265

Ser Pro Glu Ser Lieu Lleul Glin Luell

Glin Ile Lieu. Gly Val Llys Thr
29 O

Ser

Ala Luell

Arg Phe

Luell

295

Pro
285

Gly

Cys Glin Arg

Wall Ile

Pro

Asp

3 OO

Gly Ala Lieu. Tyr Gly Ser Lieu. His

Phe

Asp

310

Arg Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr
3.25

His Gly Lieu Pro Lieu. His Lieu.

Asp Glin

27 O

27s

34 O

24 O

250

His Lieu. Glu Ile Arg Glu Asp Gly

Glin

Asp Asp Ala Glin Glin Thir Glu Ala

245

3. OS

Gly Gly

Pro

Gly
345

Pro Glu Ala
315

Asn Wall
330
Asn

Lys

Ser Phe

Glin Ser Glu Ala
335
Ser Pro His
35. O

Arg Asp
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Pro Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Lieu Pro
355

360

365

Pro Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp
37 O

375

38O

Val Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg
385

390

395

4 OO

Ser Pro Ser Tyr Ala Ser
4 OS

<210s, SEQ ID NO 8
&211s LENGTH: 419
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 8

Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
1.

5

1O

15

Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met
2O

25

3O

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35

4O

45

Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
SO

55

6O

His Asn Ala Lys Thr Llys Pro Arg Glu Glu Gln Tyr ASn Ser Thr Tyr
65

70

7s

8O

Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly
85

90

95

Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile
1OO

105

11 O

Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val
115

12 O

125

Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser
13 O

135

14 O

Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145

150

155

160

Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
1.65

17O

17s

Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val
18O

185

19 O

Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met
195

2OO

2O5

His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser
21 O

215

22O

Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
225

23 O

235

24 O

Gly Ser Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin
245

250

255

Arg Tyr Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu
26 O

265

27 O

Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu
27s

28O

285

Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu.
29 O

295

3 OO
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Gly Val Lys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu.
3. OS

310

315

32O

Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu.
3.25

330

335

Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu.
34 O

345

35. O

Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Pro
355

360

365

Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro Pro Ala Lieu
37 O

375

38O

Pro Glu Pro Pro Gly Ile Leu Ala Pro Glin Pro Pro Asp Val Gly Ser
385

390

395

4 OO

Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser
4 OS

41O

415

Tyr Ala Ser
<210s, SEQ ID NO 9
&211s LENGTH: 177
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 9

Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr
1.

5

1O

15

Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg
2O

25

3O

Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu.
35

4O

45

Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val
SO

55

6O

Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly
65

70

7s

8O

Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu.
85

90

95

Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu.
1OO

105

11 O

His Leu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Pro Glin Gly
115

12 O

125

Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu
13 O

135

14 O

Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp
145

150

155

160

Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala
1.65

17O

17s

Ser

<210s, SEQ ID NO 10
&211s LENGTH: 406
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 10

Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
1.

5

1O

15
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Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met
2O

25

3O

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35

4O

45

Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
SO

55

6O

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65

70

7s

8O

Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly
85

90

95

Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile
1OO

105

11 O

Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val
115

12 O

125

Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser
13 O

135

14 O

Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145

150

155

160

Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
1.65

17O

17s

Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val
18O

185

19 O

Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met
195

2OO

2O5

His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser
21 O

215

22O

Pro Gly Lys Gly Ser Asp Ser Ser Pro Leu Lleu Glin Phe Gly Gly Glin
225

23 O

235

24 O

Val Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala
245

250

255

His Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin
26 O

265

27 O

Ser Pro Glu Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile
27s

28O

285

Glin Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp
29 O

295

3 OO

Gly Thr Lieu. Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe
3. OS

310

315

32O

Arg Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala
3.25

330

335

His Gly Lieu Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp
34 O

345

35. O

Pro Ala Ser Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro
355

360

365

Pro Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp
37 O

375

38O

Val Gly Ser Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg
385

390

Ser Pro Ser Tyr Ala Ser
4 OS

395

4 OO
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<210s, SEQ ID NO 11
&211s LENGTH: 406
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 11

Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
1.

5

1O

15

Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met
2O

25

3O

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35

4O

45

Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
SO

55

6O

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65

70

7s

8O

Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly
85

90

95

Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile
1OO

105

11 O

Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val
115

12 O

125

Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser
13 O

135

14 O

Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145

150

155

160

Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
1.65

17O

17s

Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val
18O

185

19 O

Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met
195

2OO

2O5

His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser
21 O

215

22O

Pro Gly Lys Gly Ser Asp Ser Ser Pro Leu Lleu Glin Phe Gly Gly Glin
225

23 O

235

24 O

Val Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala
245

250

255

His Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin
26 O

265

27 O

Ser Pro Glu Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile
27s

28O

285

Glin Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp
29 O

295

3 OO

Gly Ala Leu Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe
3. OS

310

315

32O

Arg Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala
3.25

330

335

His Gly Lieu Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp
34 O

345

35. O

Pro Ala Ser Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro
355

360

365

Pro Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp
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37 O

375

38O

Val Gly Ser Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg
385

390

395

4 OO

Ser Pro Ser Tyr Ala Ser
4 OS

<210s, SEQ ID NO 12
&211s LENGTH: 419
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 12

Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
1.

5

1O

15

Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met
2O

25

3O

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35

4O

45

Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
SO

55

6O

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65

70

7s

8O

Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly
85

90

95

Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile
1OO

105

11 O

Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val
115

12 O

125

Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser
13 O

135

14 O

Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145

150

155

160

Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
1.65

17O

17s

Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val
18O

185

19 O

Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met
195

2OO

2O5

His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser
21 O

215

22O

Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
225

23 O

235

24 O

Gly Ser Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin
245

250

255

Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu
26 O

265

27 O

Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu
27s

28O

285

Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu.
29 O

295

3 OO

Gly Val Lys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu.
3. OS

310

315

32O

Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu.
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3.25

330

335

Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu.
34 O

345

35. O

Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser
355

360

365

Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro Pro Ala Lieu
37 O

375

38O

Pro Glu Pro Pro Gly Ile Leu Ala Pro Glin Pro Pro Asp Val Gly Ser
385

390

395

4 OO

Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg Ser Pro Ser
4 OS

41O

415

Tyr Ala Ser
<210s, SEQ ID NO 13
&211s LENGTH: 419
212. TYPE: PRT

<213> ORGANISM: Homo sapiens
<4 OOs, SEQUENCE: 13

Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
1.

5

1O

15

Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met
2O

25

3O

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35

4O

45

Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
SO

55

6O

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65

70

7s

8O

Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly
85

90

95

Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile
1OO

105

11 O

Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val
115

12 O

125

Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser
13 O

135

14 O

Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145

150

155

160

Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
1.65

17O

17s

Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val
18O

185

19 O

Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met
195

2OO

2O5

His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser
21 O

215

22O

Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
225

23 O

235

24 O

Gly Ser Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin
245

250

255

Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu
26 O

265

27 O
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Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu
27s

28O

285

Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu.
29 O

295

3 OO

Gly Val Lys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly. Thir Lieu.
3. OS

310

315

32O

Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu.
3.25

330

335

Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu.
34 O

345

35. O

Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser
355

360

365

Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro Pro Ala Lieu
37 O

375

38O

Pro Glu Pro Pro Gly Ile Leu Ala Pro Glin Pro Pro Asp Val Gly Ser
385

390

395

4 OO

Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg Ser Pro Ser
4 OS

41O

Tyr Ala Ser

What is claimed is:

1. A fusion protein comprising an FGF21 variant and an Fc
region.
2. The fusion protein of claim 1, wherein the sequence of
said protein is selected from a sequence listed in Table 1.
k

k

k

k

k
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